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CHAPTER 1 
 
INTRODUCTION 
 
Rationale 
It is well known that potassium channels are essential for maintaining 
cellular ionic homeostasis, a key requirement for numerous biological functions, 
including proliferation, migration and apoptosis (1-5). Abundant evidence 
demonstrates that cancer cells hijack the normal physiologic function of 
potassium channels to promote tumor pathogenesis (reviewed in (6, 7)). One 
such channel deregulated in cancer, is the voltage-gated potassium (Kv) 
channel, Kv1.5. Various studies demonstrate that the Kv1.5 channel is 
downregulated in cancer and propose its downregulation contributes to cancer 
progression by promoting cancer cell survival and growth (8-15). Despite these 
observations, the mechanisms governing Kv1.5 expression in cancer have yet to 
be elucidated. Therefore, in this thesis, we begin to investigate the mechanisms 
underlying aberrant regulation of Kv1.5 channel expression and determine the 
consequences this misregulation has on cancer cell survival and cell growth. 
Investigating the contribution of Kv1.5 channel misregulations in cancer will 
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provide new insights into molecular mechanisms of cancer pathogenesis and 
offer innovative therapeutic strategies to tackle resistant cancer cells and 
relapsed disease.   
Great strides have been made in advances for cancer treatment, however 
cancer still remains the second leading cause of death in children (16). This 
thesis focuses on two aggressive pediatric solid tumors, Ewing Sarcoma (ES) 
and Neuroblastoma (NB). ES is the second most prevalent form of bone tumor in 
children and young adults and NB is the most common extra-cranial solid tumor 
of childhood. Though effective therapies have been developed, patients 
diagnosed with metastases have a low rate of survival and relapse is 
predominant as it occurs in 1/3rd of ES patients (16, 17) and 50-60% of high-risk 
NB patients (18). This indicates that at least some tumor cells survive despite 
exposure to cytotoxic drugs and an increasingly hostile microenvironment (e.g. 
hypoxia, necrosis, nutrient deprivation) (19, 20). Furthermore, relapsed ES and 
NB tumors are often highly drug resistant, thus limiting treatment options (16, 
17). These predominant issues re-enforce the need for new therapeutic 
approaches, ones that specifically target resistant cells.  
Potassium Channel Overview 
Potassium channels are a large and diverse family of ion channels. They 
are transmembrane proteins, which selectively move potassium ions (K+) into 
and out of intracellular and extracellular compartments, in response to various 
stimuli (voltage or ligand-gated) (5, 21, 22). Potassium channels are found in 
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nearly all cell types, including skeletal muscle cells, glial cells, cardiomyocytes, 
erythrocytes, pancreatic β cells, smooth muscle cells and lymphocytes (5, 22). 
They have diverse biological roles, including regulating membrane potential (23, 
24), cell volume (25), calcium signaling (26) and determining the rate of 
repolarization, especially in excitable cells such as neuronal and cardiac cells 
(23).   
Kv Channel Family 
The potassium channel family is comprised of seventy-eight members and 
its largest subset consists of the voltage-gated potassium channels (Kv) (22). 
The three other classes of the potassium channel family include, inward rectifying 
potassium channels (Kir), calcium-activated potassium channels (KCa) and two-
pore domain potassium channels (K2P). The Kv channels are a superfamily 
comprised of twelve subfamilies (Kv1-12) encoded by forty genes (22). The first 
four Kv channel subfamilies were originally cloned from Drosophila and are 
known as the Shaker (Kv1), Shab (Kv2), Shaw (Kv3) and Shal (Kv4) families 
(27). Further cloning studies led to the identification of additional Kv subfamilies, 
designated Kv5-Kv12 (22). Within each subfamily, multiple members exist (e.g. 
Kv1.1-Kv1.8); these are known as Kv α subunits.  
To form a functional Kv channel protein complex, four α subunits, each 
with six transmembrane domains (TMs), assemble into a tetrameric structure 
(Illustrated in Figures 1.1A and 1.1B). The TM1-4 helices form the voltage-
sensing region, as TM4 possesses conserved arginine residues that respond to 
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electrostatic forces (Illustrated in Figure 1.2) (28). TM5-6 and the intracellular 
loop between TM5 and TM6 form the ion-conducting pore (29-32). Within the 
pore helix is a highly conserved GYG amino acid sequence, which is crucial for 
the regulation of potassium selectivity (29-32). Kv channels can form functional 
homotetramers or heterotetramers (22). Heterotetramerization occurs with four 
Kv α subunits within the same subfamily (22). In addition to α subunits, there are 
three Kvβ subunits (Kv β1-3), which can alter the kinetics, stability and 
expression of the Kv α subunits (22).  
Kv channels play key roles in a wide variety of cellular processes including 
regulating cell growth, cell volume, motility, apoptosis, establishing resting 
membrane potential and vessel tone (1, 5, 7, 21, 22, 24). In the cardiovascular 
system, Kv channels are important for generating myocardial action potentials 
and determining action potential duration. Myocardial action potentials are 
generated from ion channels that conduct inward, depolarizing (Na+ and Ca2+) 
currents and outward, repolarizing (K+) currents (23). The Kv channels underlie 
the repolarization currents, which are important for returning membrane potential 
to its resting state. Kv channels play a role in both the early and late phases of 
repolarization in the action potential, as they encode two types of Kv currents: 
transient outward currents (Ito) and delayed rectifier currents (23). Similar to 
myocardial action potentials, Kv channels are also important in neuronal 
excitability, as they are important for the repolarization of the neuronal action 
potential (33). In the vasculature (e.g. pulmonary and cerebral), Kv channels play 
an integral role in the myogenic response. In particular, Kv channels establish 
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vessel tone, maintain resting membrane potential and regulate blood pressure as 
they promote vasodilation (21, 34).  
It is well known that Kv channels play an essential role in maintaining a 
balance between cell survival and apoptosis and cell growth/proliferation, as they 
regulate intracellular potassium concentrations (1, 5). Seminal work in 
lymphocytes demonstrated that changing intracellular potassium concentrations 
altered a cell’s ability to respond to cell death signals (35). In healthy cells, the 
intracellular potassium concentration ([K+]i) sits at ~145-150 mM (36-38). If a 
cell’s [K+]i is at normal to high levels (~150-200 mM), caspase activation is 
suppressed, however once [K+]I falls to low levels (≤100 mM), caspases are 
activated (35, 36, 38, 39). Therefore, a threshold level of [K+]i must be reached 
before caspase activation occurs (35, 40). Mechanistically, caspase activation is 
inhibited by normal to high levels of [K+]i (150-200 mM) as a result of K+-
dependent inhibition of Apaf-1 oligomerization, a key requirement for formation of 
the apoptosome (40, 41). In cell growth and proliferation, Kv channels contribute 
to the regulation of membrane potential (Vm) (1, 3, 4, 24, 42). The Vm of cells 
changes throughout the cell cycle. Specifically, a hyperpolarization occurs at the 
G1-S transition due to potassium efflux through Kv channels (1, 43) and 
depolarization occurs at the G2-M transition (43, 44). Therefore, changes in Kv 
channel expression can significantly alter potassium flux in the cell and affect cell 
cycle regulation. 
Given the vast roles of Kv channels in cell physiology, it is not unexpected 
that dysregulation of Kv channels is linked to numerous disease states, including 
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atrial fibrillation (AF) (45), pulmonary arterial hypertension (PAH) (46), heart 
failure (47), and cancer (7, 48, 49).  
Structure of the Kv1.5 Channel 
Within the Kv channel family, a key channel of interest, and the focus of 
this thesis, is the Kv1.5 channel. The Kv1.5 channel consists of four α subunits, 
which generate homo- or hetero-tetramers. The Kv1.5 α subunits can associate 
with Kvβ ancillary subunits. Three Kvβ subunits have been shown to interact with 
the Kv1.5 channel, Kvβ1.2, Kvβ1.3 and Kvβ2.1 (50-52). Kvβ subunits are 
important as they participate in Kv1.5 α subunit assembly in the endoplasmic 
reticulum (53), aid in transport to the plasma membrane (51) and modulate 
activation and inactivation kinetics of the Kv1.5 channel current, IKur (54-56). 
 There are two types of inactivation mechanisms for Kv1 channels, N-type 
and C-type (57-59). Co-expression of Kv1.5 with a Kvβ subunit results in N-type 
inactivation. This occurs when the inactivation peptide, located on the N-terminus 
of the β subunit, enters the inner cavity of the channel pore and obstructs ion 
passage (60). Inactivation of the Kv1.5 channel alone is of the C-type. This form 
of inactivation is due to conformational changes around the exterior mouth of the 
pore, which inhibit access to the selectivity filter (56).  
The Kv1.5 channel is part of the voltage-gated Kv channel family, whose 
role is to regulate potassium ion flux in response to alterations in the membrane 
potential, making Kv channels responsible for establishing the resting membrane 
potential in cells (23, 61, 62). Kv channels possess voltage-sensor domains, 
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which are positioned at the periphery of the channel and consist of the S1-S4 
transmembrane segments (Figure 1.2) (31, 63). The voltage-sensor domains 
respond to changes in membrane potential, in particular the S4 segment, as it 
possesses positively charged arginines, causing structural re-arrangement (31, 
63). The structural re-arrangement results in a conformational change in the 
conduction pore, which can either promote or occlude passage of potassium 
through the channel and down its concentration gradient (31, 63).  
Another unique feature of the Kv1.5 channel is that it is an oxygen sensor, 
meaning it possesses an oxygen (O2)-sensitive current. Specifically, potassium 
flux through the channel can be increased or decreased upon exposure to 
reactive oxygen species (ROS) (46, 64). Though controversial as to its effect, it is 
known that the Kv1.5 channel current is responsive to ROS (46, 64-66). 
Currently, the molecular physiology underlying O2 sensitivity of the Kv1.5 channel 
remains unclear. However, work with other O2-sensitive Kv channels (i.e. Kv1.2, 
Kv2.1, Kv3.1, Kv3.3, Kv4.2 and Kv9.3), has identified key channel components 
regulated by ROS (67). Specifically, ROS oxidize thiol-containing residues 
(cysteine and methionine) in the N-terminus of the Kv channel, which results in 
the formation of disulfide bridges with other thiol-residues in the channel (68). 
The disulfide bridges physically prevent channel inactivation and therefore 
promote Kv channel current (69-71). The Kvβ subunits also play a role in redox 
sensing, as each subunit possesses the oxygen-binding protein, NAPDH oxidase 
(72). In the presence of oxygen, NAPDH becomes oxidized (NADP+) and 
produces ROS, which can oxidize thiol-residues and contribute to Kv channel 
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inactivation (70-72). However, this can only occur if the β subunit is coupled to a 
Kv channel (70-72).   
Kv1.5 Channel Function in Physiological and Pathological Conditions 
Kv1.5 channel expression is detected in many cell types in the human 
body, including atrial myocytes (45), pulmonary arterial smooth muscle cells 
(PASMCs) (73, 74), GH3 pituitary cells (75, 76), oligodendrocyte precursor cells 
(77, 78), macrophages (79), somato dendritic Purkinje cells of the cerebellum 
(80) and cancer cells (7, 81). Aside from its diverse expression, the Kv1.5 
channel is of particular importance in O2-sensitive tissues, as it possesses an O2-
sensitive channel and its expression, at both a protein and transcript level, is 
directly altered by oxidative factors, mainly HIF-1α (82) and hydrogen peroxide 
(H2O2) (83). Therefore, it is no surprise that due to its voltage and oxygen-
sensitivity the Kv1.5 channel has a dynamic role in physiologic and 
pathophysiological states that are associated with ROS and oxidative stress. In 
fact, most of what is known about Kv1.5 channel function stems from its role in 
disease, particularly atrial fibrillation (AF), pulmonary arterial hypertension (PAH) 
and brain ischemia. 
Atrium 
In the cardiovascular system, specifically in the human atrium, Kv1.5 
underlies the ultra-rapid delayed recitifier current (IKur), important for atrial 
repolarization and action potential duration (84, 85). Therefore, the Kv1.5 
channel is important for returning the membrane potential of atrial myocytes from 
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a depolarized state (~ 52 mV) back towards its resting membrane potential (~-80 
mV) (23). This is accomplished through the movement of potassium down its 
concentration gradient, which results in the efflux of potassium out of the cell, 
driving the membrane potential towards a negative membrane voltage. In atrial 
myocytes, the Kv1.5 channel current is activated at potentials in the range of -20 
mV to + 50 mV (86, 87). Interestingly, the reported activation of the voltage-
sensitive Kv1.5 channel current is slightly different in varying tissues. For 
example, heterologous expression of the Kv1.5 channel in mouse cells, Kv1.5 
channel current activates at potentials between -10 to +60 mV and partially 
inactivates at +60 mV (88). Despite the slight differences, the purpose of the 
activation range of the Kv1.5 channel current is to establish the resting 
membrane potential in many cells, particularly in vascular smooth muscle.  
Vascular smooth muscle cells, and likely cancer cells, are both examples 
of tissues with small-size cells and high input resistance.  This makes the cells 
particularly sensitive to changes in membrane potential, with small changes in 
potential leading to large changes in the opening of channels and therefore 
potassium ion current.  Because the flux of potassium is essential for maintaining 
cellular ionic homeostasis and critical for regulating cellular processes, this 
implies that small changes in membrane potential can have profound effects on a 
cells ability to function normally. Thus, the precise biophysical characterization of 
the Kv1.5 channel remains an area of extensive research in relation to both 
healthy and diseased states. 
 
 
 
 
 
10 
Kv1.5 is best known for its role in cardiovascular disease, in particular 
atrial fibrillation (AF) (45). AF is the most common cardiac arrhythmia present in 
the population. Shortening of the atrial effective refractory period of the atrium is 
an important factor in acute and persistent AF. As previously mentioned Kv1.5 
underlies the IKur current, which is important for atrial repolarization and action 
potential duration (84, 85). An early study established that patients in chronic AF 
have electrophysiological and physiological remodeling and a consequence of 
this remodeling is the downregulation of Kv1.5 channel expression (45). One 
aspect associated with structural and electrical remodeling of the heart in AF, is 
the excessive production of ROS (89). The modulation of Kv1.5 by ROS still 
remains unclear, however it was discovered that H2O2 activates Kv1.5 channel 
current in acute AF (83). Furthermore, the activation of Kv1.5 reduces action 
potential duration and leads to the shortening of the atrial refractory period and 
therefore it is hypothesized to initiate and/or contribute to the duration of AF (83). 
In particular, it is thought that initial activation of the Kv1.5 channel in acute AF 
contributes to the continuation of AF, leading to chronic AF and the eventual 
downregulation of the Kv1.5 channel (83). Therefore, it is clear that the Kv1.5 
channel and its IKur current function to maintain normal physiologic cardiac 
rhythm.  
Pulmonary Vasculature 
PASMCs rely on Kv channels, in particular the Kv1.5 channel, to 
determine resting membrane potential and the concentration of cytosolic free 
Ca2+ (90). In the pulmonary vasculature, exposure to acute hypoxia inhibits Kv 
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channels, increases cytosolic Ca2+, depolarizes the PASMCs and causes 
pulmonary vasoconstriction (46). In the pathophysiological disease, pulmonary 
arterial hypertension (PAH), hypoxia initiates vasoconstriction as an adaptive 
mechanism to redistribute blood flow to better-oxygenated areas of the lungs 
(91). Hypoxic pulmonary vasoconstriction is mediated by the inhibition of Kv 
potassium channels in PASMCs, predominantly via acute downregulation of the 
O2-sensitive Kv1.5 channel (82, 90, 92, 93). In PAH, conditions of acute and 
chronic hypoxia result in the significant downregulation of Kv1.5 channel 
expression and the Kv1.5-encoding gene transcript KCNA5 (82, 94-97). 
Therefore, loss of Kv1.5 expression in is a contributing factor in the pathogenesis 
of PAH (95, 98, 99).  
Recently, it was discovered that the Kv1.5 channel is part of a key 
pathway, the mitochondria-ROS-HIF-Kv pathway, whose disruption contributes to 
the development of PAH (100). It was elucidated that under hypoxic conditions, 
HIF-1α represses KCNA5 and ROS withdrawal inhibits the opening of Kv1.5 
channels (46). This results in pulmonary vasoconstriction, the eventual 
hyperpolarization of the mitochondria and ultimately disrupts the mitochondria-
ROS-HIF-Kv pathway (46). Furthermore, re-introducing the Kv1.5 channel 
improves pulmonary hypertension, as it restores the O2-sensitive current and 
reduces pulmonary vascular resistance (82). Interestingly, the Kv1.5 channel 
also underlies mitochondrial-mediated cell death in PAH, due to its involvement 
in the mitochondria-ROS-HIF-Kv pathway and the discovery that the pro-
apoptotic activator cytochrome-c activates Kv channels, while the anti-apoptotic 
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bcl-2 inhibits Kv channels (101). Together, this demonstrates that the function of 
Kv1.5 in the pulmonary vasculature is to maintain vessel tone, regulate an 
adaptive response to hypoxic stress and mediate apoptotic cell death. 
Brain 
Impaired blood flow in the brain produces injury and brain ischemia. 
Exposure of the brain to short periods of noninjurious ischemia (pre-
conditioning), results in ischemic tolerance, meaning the brain does not sustain 
injury when exposed to a subsequent ischemic insult (102, 103). It was 
discovered that in response to ischemia, ischemic-tolerant brains suppressed 
gene expression (103). Interestingly, genomic analysis revealed that a unique 
feature of ischemic-tolerant brains was the suppression of outward potassium 
currents, in particular the downregulation of KCNA5 and its β-subunit KCNAB2 
(103). Furthermore, it was demonstrated that an epigenetic mechanism, involving 
polycomb group (PcG) proteins, suppressed KCNA5. The PcG protein BMI-1 
was found to bind and alter KCNA5 expression, ultimately affecting the 
functionality of potassium currents (103) (See Section Below: Epigenetic 
Mechanisms in Cancer). Thus, the function of Kv1.5 in the brain, aside from 
maintaining vessel tone in the vasculature (104), is to regulate ischemic 
tolerance, an adaptive response to oxygen limitation.  
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Regulation of Kv1.5 Channel Expression 
Kv1.5 channel expression is regulated at the level of the protein and at the 
transcript through diverse mechanisms. This section focuses on protein 
regulation, post-translational modifications and transcription factors. 
Protein Trafficking and Localization 
Steady-state expression of the Kv1.5 channel at the cell-surface is a 
function of protein trafficking and localization. Scaffolding proteins and 
anterograde and retrograde trafficking pathways all function to regulate Kv1.5 
channel surface expression. Scaffolding proteins function to stabilize Kv1.5 at the 
cell surface through regulating its localization within the plasma membrane (105, 
106). In particular, membrane-associated guanylate kinase (MAGUK) proteins, 
such as synapse-associated protein 97 (SAP97), bind to Kv1.5 and target it to 
special domains at the cell surface (e.g. intercalated disk) (105). Anterograde 
trafficking of the channel occurs via the dynein motor along microtubules (107-
109) and the myosin-V-A motor along actin filaments (110). Retrograde 
trafficking of the Kv1.5 channel is a Rab-GTPase specific process where 
individual Rab proteins have unique functions. Association with Rab4- or Rab11-
endocytic vesicles recycles Kv1.5 to the surface, while association with the 
Rab7-endocytic vesicle results in Kv1.5 degradation (108, 111). Recent evidence 
also demonstrates that the myosin-V-B motor mediates post-endocytic recycling 
of Kv1.5 and this is dependent on coupling to Rab11 (110).   
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Post-Transcriptional Modifications 
Post-translational modifications of Kv1.5 channels regulate surface 
expression, stability and biophysical properties of the channel. Numerous post-
translational modifications of the channel have been identified, including 
phosphorylation, sumoylation, nitrosylation, palmitoylation, glycosylation, 
thioacylation, ubiquitination and sulfenic acid modification. Sumoylation, 
phosphorylation and nitrosylation all affect the biophysical properties of the Kv1.5 
channel. Sumoylation regulates Kv1.5 channel inactivation (112), nitrosylation 
has been shown to decrease the Kv1.5 channel current IKur (113), and 
phosphorylation impacts the amplitude of the IKur current. Specifically, PKA 
increases (114-116) whereas PKC-mediated phosphorylation decreases IKur 
amplitude (117). Palmitoylation (118) and glycosylation (119) both impact Kv1.5 
channel localization to the plasma membrane and therefore affect its surface 
expression. Thioacylation regulates steady-state expression of Kv1.5 as 
mutations of these residues increased Kv1.5 cell surface expression (120). 
Lastly, sulfenic acid modification (121) and ubiquitination (122) of Kv1.5 targets 
the channel for degradation.  
Transcription Factors 
As Kv1.5 channel expression is significantly altered in PAH and AF, the 
transcriptional machinery controlling expression of KCNA5 has predominantly 
been determined in these pathophysiological diseases. Currently, three main 
transcription factors, Sp1, HIF-1α and NFAT, have been determined to directly 
affect KCNA5 expression (92, 123, 124).  
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Sp1 is a triple zinc finger protein that binds G/C rich nucleotide 
sequences, including GC and CACCC boxes, and is a modulator of tissue 
specific transcription (124). The KCNA5 promoter activity in vascular smooth 
muscle is dependent on Sp1 regulation through CACCC box motifs. Inhibition of 
Sp1-KCNA5 promoter interactions prevented promoter activity, while expression 
of exogenous Sp1 augmented promoter activity (124). While Sp1 promotes 
KCNA5 transcription, HIF-1α and NFAT repress KCNA5 transcription. 
Interestingly, a negative correlation between the transcription factors HIF-1α and 
NFAT, and Kv1.5 expression has been found in PASMCs (92, 123). Evidence 
demonstrates that blocking HIF-1α activation using a dominant-negative HIF-1α 
restores KCNA5 transcript and Kv1.5 expression and function (100). 
Furthermore, the presence of the RCGTG binding motif, a core-binding motif of 
HIF-1α, in the KCNA5 promoter suggests that HIF-1α directly binds the KCNA5 
locus (125, 126). Though HIF-1α has been demonstrated to repress KCNA5 
transcription, opposing literature suggests HIF-1α induces Kv1.5 channel 
expression (127), adding debate to the field. In PAH, loss of Kv channels, 
especially Kv1.5, causes membrane depolarization in PASMCs and results in an 
elevation of cytosolic Ca2+. The increase in Ca2+ then activates the transcription 
factor, NFAT (128). Activation of NFAT reinforces the downregulation of the 
Kv1.5 channel through repression of KCNA5 (128). Multiple NFAT binding 
elements, GGAAA, are present in the KCNA5 promoter, suggesting that NFAT 
binds the KCNA5 locus. Of the four isoforms of NFAT, NFATc1-c4, NFATc2 is 
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the predominant isoform in PAH that has been demonstrated to repress KCNA5 
(123, 129).  
Aberrant Expression of Kv1.5/KCNA5 in Cancer 
Aberrant expression of ion channels is prevalent in cancer and 
dysregulation of potassium channels has, in particular, been well documented 
(see recent reviews (7, 13, 49)). In general, expression of potassium channels is 
mostly upregulated in cancer (Illustrated in Table 1), and upregulation is a 
consequence of cancer cell transformation (7). Since potassium channels 
influence many cell behaviors, all of which are important for cancer 
pathogenesis, the hijacking of potassium ion channel function by malignant cells 
in not surprising (Illustrated in Table 2). Significantly, however, though most 
channels are upregulated in cancer, two channels are uniquely downregulated, 
and one of these is Kv1.5 (KCNA5) (9-12, 14, 15, 81) (Illustrated in Table 1). 
Overall, the net effect of potassium channel deregulation can have a tumorigenic 
or tumor suppressive impact, depending on the channel and the cellular context. 
Thus, elucidation of the role and mechanism of Kv1.5 downregulation in cancer 
has the potential to offer new insights into tumor pathogenesis.  
Genetic Abnormalities 
Recent studies observe a dysregulation in Kv1.5 expression in human 
cancer. Specifically, Kv1.5 expression is downregulated and its expression is 
inversely correlated with tumor aggression in gliomas and lymphomas (8, 10-12, 
14, 15, 130). Further observations note that the mutation rate of KCNA5 across 
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multiple cancer types is less that 10% and only a few of these somatic mutations 
are predicted to result in a gain or loss of KCNA5 function (the results shown 
here are in part based on data generated by the TCGA Research Network: 
http://cancergenome.nih.gov/ and (131)). Furthermore, recurrent deletions have 
yet to be described for this gene. Together these observations suggest that the 
downregulation of KCNA5 in cancer is unlikely to be caused by genetic 
mutations. Thus, the mechanism(s) underlying Kv1.5 channel and KCNA5 
transcript downregulation remain to be elucidated and we aim to fill this gap with 
the work presented in this thesis. 
Cell Proliferation and Apoptosis 
The Kv1.5 channel has been shown to regulate the G1/S transition in the 
cell cycle (132, 133). It was discovered that Kv1.5 inhibited skeletal muscle cell 
proliferation at the G1/S transition, through a mechanism that increased cyclin-
dependent kinase inhibitors p21 and p27 and decreased expression of cyclins A 
and D1 (133). Therefore, it is hypothesized that the Kv1.5 channel is a G1/S 
checkpoint regulator and cancer cells downregulate its expression to promote 
cell cycle progression. However, in contrast to the previous study, 
pharmacological inhibition of the Kv1.5 channel was shown to block B-
lymphocyte proliferation and arrest cells in the G1 phase (15). Together, this 
evidence suggests that the Kv1.5 channel has cell-type specific function. 
As mentioned previously, the Kv1.5 channel is important for maintaining a 
balance between cell survival and apoptosis in non-transformed cells (1, 8, 45, 
46, 134, 135). As Kv1.5 and KCNA5 expression are downregulated in many 
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human cancers (e.g. glioblastoma and lymphoma), it is hypothesized that this 
downregulation contributes to cancer cell survival (8, 10-12, 14, 15). Two studies 
specifically demonstrate an effect of Kv1.5 expression on apoptosis in cancer 
cells. In lymphocytes, downregulation of Kv1.5 expression prevented apoptosis 
(10), while in several cancer cell lines, including M059K (glioblastoma),  A549 
(non-small-cell lung) and MCF-7 (breast) cancer cells (8), reactivation of the 
Kv1.5 channel induced apoptosis. Interestingly, in the cell line study it was 
discovered that the transcription factor, NFAT directly represses KCNA5, and 
release of this repression leads to apoptotic cell death (8). Combined, these 
studies demonstrate that the Kv1.5 channel has an inherent role in governing 
cancer cell fate. However, despite these studies, a gap remains in understanding 
the mechanism(s) underlying regulating Kv1.5 expression.  
As discussed above, potassium channels have many roles in tumor 
biology. However, the involvement of potassium channels in cancer 
tumorigenesis is still an emerging field and it is clear that potassium channels 
have cell-type specific functions. Therefore, it is necessary to continue to define 
the roles of specific potassium channels such as Kv1.5, in cancer biology. We 
focus on the Kv1.5 channel, in particular, as it possesses oxygen and voltage-
sensitivity, which we hypothesize, contributes to its role in cancer. As mentioned 
previously, the oxygen-sensitivity and voltage-sensitivity of the Kv1.5 channel is 
dependent on its environment and these aspects of the Kv1.5 channel have yet 
to be explored in cancer. This thesis begins to address those gaps in knowledge 
by investigating the function and role of the Kv1.5 channel in the two pediatric 
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solid tumors, ES and NB. In addition to understanding the roles of potassium 
channels in cancer biology, studies also need to address the mechanisms 
regulating channel expression, as it will be necessary for the development of 
targeted therapies that seek to exploit the tumor-specific nature of potassium 
channel deregulation. Finally, understanding the influence of the 
microenvironment and its stressors on potassium channel regulation will also be 
pertinent to understanding how to manipulate such mechanisms.  
Pediatric Cancer: A Clinical Problem 
As previously mentioned this thesis focuses on the two pediatric solid 
tumors, Ewing Sarcoma (ES) and Neuroblastoma (NB). Though effective 
treatment regimens have been developed, a predominant issue associated with 
these tumors is they are plagued by relapse. However, before proposing new 
therapeutic avenues, let me first describe the treatment backbone of these 
diseases at diagnosis.  
Upon diagnosis and following tumor staging, standard chemotherapy 
induction agents used in ES patients include alternating cycles of vincristine, 
doxorubicin, cyclophosphamide, ifosfamide and etoposide, known as the VDC-IE 
regime (17). In NB patients, the standard chemotherapy induction agents used 
include, vincristine, doxorubicin, cyclophosphamide and topotecan (16, 18). 
Given the aggressive nature of ES and NB, treatment regimens consist of a 
combination of chemotherapy, surgery and radiation.  
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Relapsed ES and NB tumors are often highly resistant to cytotoxic drugs 
and micro-environmental stressors, limiting treatment options and re-enforcing 
the need for new therapeutic avenues. Recent discoveries have determined that 
ES and NB are epigenetically driven diseases, as disruptions in epigenetic 
machinery contribute to the initiation and progression of these tumors. Therefore, 
understanding how these tumors manipulate epigenetic mechanisms will provide 
novel therapeutic targets that can be incorporated into ES and NB treatment 
regimens.  
Epigenetic Mechanisms in Cancer 
Epigenetics 
Traditionally, cancer was considered to be a disease solely driven by an 
accumulation of genetic mutations (19). Over the last decade, we have learned 
that epigenetic abnormalities are equally important drivers of cancer 
tumorigenesis, thus causing a paradigm shift (136). Epigenetics is defined as a 
heritable change in gene expression not caused by alterations in DNA sequence. 
Epigenetic regulation of gene expression is achieved through three over-arching 
mechanisms: DNA methylation, histone modifications and chromatin remodeling 
(Illustrated in Figure 1.3).  
CpG rich sequences, known as CpG islands, are targets of DNA 
methyltransferases (DNMTs) and these enzymes methylate cytosines at the 5’-
position (Figure 1.3A). There are two groups of DNMTs, de novo DNMTs (137), 
which newly methylate cytosines, and maintenance DNMTs (138), which 
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methylate a DNA strand if its partner strand is already methylated. In general, 
DNA methylation modifies gene expression by silencing genes. This occurs 
through hypermethylation of promoters, which then can directly (139) and 
sterically (140-142) prevent transcription factors from accessing the DNA and 
initiating transcription.  
Chromatin is a condensed form of DNA that serves as a way to control gene 
expression. The basic structure of chromatin consists of the nucleosome, which 
is a complex of DNA wrapped around a histone octamer. Nucleosomes can be 
packed together to form condensed chromatin, known as heterochromatin, or 
they can be loosely spaced apart, a chromatin state known as euchromatin. 
Gene expression occurs in the euchromatin state, while heterochromatin lacks 
gene transcription. Epigenetic regulation influences gene expression by altering 
the chromatin state largely through the use of post-translational modifications 
and chromatin remodeling complexes.  
Post-translational histone modifications occur either on histone tails or the 
core histones, and they contribute to gene regulation. There are a variety of 
histone modifications, including acetylation, methylation, phosphorylation, 
ubiquitination and sumoylation, and these modifications are associated with 
transcription activation or repression (Figure 1.3B). Proteins that regulate histone 
modifications are known as histone regulators and three classes exist: writers, 
which add the marks; erasers, which remove the marks; and readers, which 
recognize specific modifications and recruit translational machinery. The two 
main and well-studied histone modifications are acetylation and methylation. 
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Acetylation of lysine residues on the tails of histones H3 and H4 is associated 
with transcription activation. The writers for acetylation are histone 
acetyltransferases (HATs) (e.g. CBP) and these marks are in turn erased by 
histone deacetylases (HDACs) (i.e. HDAC1-3) (143). There are three levels of 
methylation, mono-, di- and tri-methylation that occur at lysine residues on the 
tails of histone 3. The writers for methylation are histone methyltransferases 
(HMTs) and the erasers are histone demethylases (e.g. LSD1, JMJD2C) (144, 
145). There are two main classes of HMTs, the proteins that promote 
transcription and the proteins that silence transcription. The Trithorax group 
proteins methylate lysine 4 on histone 3 by the mixed lineage leukemia (MLL) 
genes, MLL1-3, and they promote transcription. PcG proteins are composed of 
two main complexes, polycomb repressive complex 1 (PRC1) that 
monoubiquinates lysine 119 on histone H2A and polycomb repressive complex 2 
(PRC2), which functions to methylate lysine 27 on histone 3, both histone 
modifications silence transcription. In stem cells, PcG proteins are important for 
silencing genes involved in differentiation, and in so doing maintain self-renewal 
and pluripotency (146). Lastly, the readers of all histone modifications are 
chromatin-associated proteins (e.g. HP1, MeCP2), which maintain or alter the 
chromatin, respectively (147, 148).  
The mechanisms that alter the structure of chromatin are ATP-dependent 
multiprotein complexes, known as chromatin remodelers. These complexes use 
the energy from the hydrolysis of ATP to reposition nucleosomes and remove or 
exchange histones, creating open or closed regions of DNA (149, 150) (Figure 
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1.3C). There are five families of chromatin remodelers: SWI/SNF, ISWI, 
NuRD/Mi-2/CHS, INO80 and SWR1 (Figure 1.3C). These complexes can 
restructure chromatin to either an active or inactive state, which influences 
accessibility of transcription factors to promoter regions; therefore chromatin 
remodelers can both activate and silence gene expression. 
Epigenetic Dysregulation 
Cancer cells hijack epigenetic mechanisms to alter gene expression. In 
particular, cancer cells use epigenetic mechanisms to aberrantly silence 
regulatory and tumor suppressor genes, to promote uncontrolled tumor growth 
and survival.  
Early studies revealed cancer cells have different DNA methylation 
patterns compared to normal cells. It was discovered that cancer cells 
hypomethylate intergenic regions of genes and hypermethylate the promoter 
region of genes (141, 151-153). The regions that are targets of hypermethylation 
contain CpG islands and are frequently associated with tumor suppressor genes, 
(e.g. Retinoblastoma (pRb)) (154). While the role of promoter hypermethylation in 
cancer is generally understood, the role of intergenic hypomethylation remains 
unclear. It is currently proposed that loss of methylation results in genomic 
instability, which promotes overexpression of certain genes (e.g. CD30, 
CYCLIND2) (155, 156) and thus drives disease progression (157). Furthermore, 
though it is observed that DNMTs and DNA methylation binding proteins are 
slightly elevated in human tumors, it is currently unknown as to their role in the 
epigenome changes that occur in cancer.  
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In cancer cells, a global change is also seen in histone acetylation and 
methylation. Genome-wide profile analysis of histone modifications in cancer 
cells discovered a loss of monoacetylation of lysine 16 and trimethylation of 
lysine 20 on histone 4 (158). Furthermore, a gain in methylation of the specific 
lysine residue 27 on histone 3 is seen in cancer cells (143, 159). The alterations 
of histone modifications in cancer are due to a disruption in their regulators. The 
loss of acetylation is due to translocations and inactivating mutations of HATs, as 
seen with CBP in leukemia (158). HDACs can also be targeted for inactivation, 
as with HDAC2 (160); however they can also be overexpressed in other cancer 
types (143). The alteration of HMTs in cancer varies depending on its associated 
histone modification, as HMTs associated with lysine 27 on histone 3 can be 
overexpressed (e.g. EZH2), while HMTs associated with lysine 9 on histone 3 
can be downregulated (e.g. RIZ1) (143). Therefore, the changes in expression of 
histone regulators are tumor specific and can have various effects on tumor 
biology. 
Nucleosome remodeling is an important component of gene silencing in 
cancer. It is well known that mutations in the SWI/SNF complex and the nine 
genes encoding SW/SNF complex subunits, occur in 20% of all human cancers 
(161-163). Furthermore, recent studies have determined that these mutations 
result in the dysregulation of numerous pathways (e.g. retinoblastoma (164) and 
MYC (165) function), which directly contribute to tumorigenesis (166-168). 
Ultimately, the importance of chromatin remodelers is linked to DNA methylation 
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(169, 170) and histone modifications (171, 172), as it is the interaction amongst 
all three players that dynamically regulates gene expression (136).  
Abnormalities in ES and NB 
Recent studies have determined that ES and NB are epigenetically driven 
diseases, as disruptions in epigenetic machinery were found to contribute to the 
initiation and progression of these tumors (reviewed in ((173)). Key drivers of ES 
and NB tumorigenicity are the PcG proteins, BMI-1 and EZH2 (174-178). 
Overexpression of BMI-1 and EZH2 are important in ES and NB tumors, as they 
maintain cancer cells in a stem-like state and support oncogenesis by 
suppressing tumor suppressor genes and developmental regulators (146, 174-
179). Furthermore, preliminary studies suggest that the overexpression of PcG 
proteins contribute to alterations in another epigenetic mechanism, DNA 
methylation. Initial studies in ES reveal that CpG islands of PcG target genes are 
hypermethylated (Lawlor lab, unpublished) and genome-wide microarray data in 
NB reveals a direct correlation between EZH2 and DNMT1 (173). Together, 
these data suggest that PcG proteins may recruit DNMTs to induce permanent 
gene silencing of key loci. Therefore, targeting specific epigenetic mechanisms, 
such as PcG proteins, is a promising approach to inhibiting ES and NB 
tumorigenicity and preventing relapse.  
In this thesis, we test the hypothesis that downregulation of the Kv1.5 
channel in ES and NB cells promotes tumor pathogenesis, and that this is 
achieved through the impact of channel dysregulation on cell death and 
proliferation. Further, in light of the lack of evidence for genetic mutation of 
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KCNA5, this thesis investigates the contribution of epigenetic mechanisms as 
mediators of Kv1.5 channel suppression.  
Thesis Summary 
The aim of this thesis is to better understand the mechanisms underlying 
Kv1.5 channel dysregulation in human cancer and to elucidate the contribution of 
Kv1.5 downregulation to cancer cell biology. In Chapter Two, we investigate 
epigenetic silencing of KCNA5 by PcG proteins and how it promotes cancer cell 
survival under conditions of physiological stress. This was accomplished through 
genetic and pharmacologic modulation of Kv1.5 channel function and PcG 
proteins and KCNA5 promoter analysis under ambient (21% O2) and stress-
inducing (hypoxia (1% O2) and growth-factor deprivation) conditions. We 
discovered that ES and NB cells are resistant to stress-induced cell death and 
this resistance is mechanistically linked to downregulation of Kv1.5 channel 
activity. Further, we determined that suppression of the Kv1.5 channel is 
mediated by polycomb-dependent repression of the KCNA5 locus. In Chapter 
Three, we investigate whether the KCNA5 promoter is hypermethylated in Ewing 
sarcoma and its consequence on ES cell biology. This was determined using two 
methylation assays: an Illumina GoldenGate® methylation array and MethyLight, 
and pharmacologic modulation of DNA methyltransferases and Kv1.5 channel 
function. In these studies, we found that the KCNA5 promoter is hypermethylated 
in ES and other cancer types. Furthermore, we determined that the promoter can 
be demethylated and transcript expressed upon exposure to the hypomethylating 
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agent, decitabine. Interestingly, decitabine treatment leads to a significant 
decrease in ES cell growth, which is partially reversed through pharmacologic 
inhibition of the Kv1.5 channel. Together these chapters implicate that epigenetic 
repression of KCNA5 promotes two key components of tumor pathogenesis, cell 
survival (Chapter Two) and cell proliferation (Chapter Three).  
The final chapter of this thesis discusses the therapeutic implications of 
understanding how the KCNA5 locus is epigenetically regulated. Specifically, it 
focuses on epigenetic modifiers and ion channel targeted therapy in cancer. 
Furthermore, this chapter explores the future potential of Kv1.5 channel research 
in relation to cancer stem cells and the mitochondria. Together, the Kv1.5 
channel makes an important target in cancer due to its unique properties of 
voltage and oxygen-sensitivity, which contribute to its involvement in mediating 
cell survival and cell proliferation. Therefore, fully understanding its regulation will 
provide another mechanism that can be therapeutically exploited, which is of key 
importance in cancer relapse. 
I would like to acknowledge the work from our collaborators, as their help 
contributed to the formulation of this thesis. Dr. Daniel J. Weisenberger and Dr. 
Peter W. Laird at the University of Southern California carried out the MethyLight 
analysis shown in Figure 3.1B. The primary Ewing sarcoma tumor samples 
analyzed in the studies in Figure 3.1B were kindly provided by Dr. Scott 
Borinstein at Vanderbilt. 
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Figure 1.1. Representation of a Shaker Kv Channel structure.  
(A) Stereoview of a Kv channel from the side, represented in ribbon diagram. The 
four α-subunits are a different color and include the voltage sensor and pore, the 
T1 domain and the β-subunit tetramer. TM represents the transmembrane 
spanning segments. (B) Tetramer structure of a Kv channel from the extracellular 
side of the pore. Provided by (32) in (A) and (31) in (B). 
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Figure 1.2. Topology of the α-Subunit of a Kv Channel. 
The α-subunit consists of six transmembrane segments (S1-S6). S1-S3 
segments are colored blue, the positively charged S4 region is red and S5-S6 
segments are yellow. The N- and C-terminal domains of the α-subunit are 
located on the intracellular side. Provided by (30). 
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Figure 1.3. Gene Expression is Regulated by Three Epigenetic Mechanisms.    
(A) DNA methylation is a biochemical process where a methyl group is placed on 
cytosine nucleotides. DNA methylation predominantly occurs at CpG islands in 
the genome. DNA methyltransferases (DNMTs) place a methyl group on the 5’ 
position of cytosine nucleotides. (B) DNA wraps around histones, composed of 
two H2A-H3B dimers and a H3-H4 tetramer. Histones have a feature of long tails 
and this is the location of post-translational modifications, known as histone 
modifications. There are numerous modifications that can occur and they include 
methylation, acetylation, phosphorylation and ubiquitination, all of which can 
positively or negatively regulate gene expression. (C) Modification of the 
chromatin structure to allow access to regulatory transcriptional machinery 
occurs via chromatin remodeling complexes. There are currently five known 
chromatin remodelers, SWI/SNF, ISWI, NuRD/MI-2/CHD, INO80 and SWR1. 
Adapted from (180) in (A), Luong, P. Basic Principles of Genetics Lecture Series 
in (B) and provided by (181) in (C).  
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Table 1. Potassium Channel Expression in Cancer.  
Information provided by (7).  
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Table 2. Cell Behaviors Potassium Channels Influence in Cancer. 
Information provided by (49).  
Protein Gene Migration Proliferation Apoptosis Angiogenesis 
Kv1.1 KCNA1   Macrophages  
Kv1.3 KCNA3   Blood Cells  
Kv1.5 KCNA5   Macrophages  
Kv10.1 KCNH1 AML and 
Breast 
Cervix, 
Neuroblastoma 
and Breast 
 Cellular 
models 
Kv10.2 KCNH5  Medulloblastoma   
Kv11.1 KCNH2 AML, 
Thyroid 
and 
Breast 
  Glioblastoma 
Kir1.1 KCNJ1   Blood cells  
Kir3.4 KCNJ5  Adrenal   
K2P5.1 KCNK5  Breast   
K2P9.1 KCNK9 Breast Breast Breast, 
Neurons and 
Glioma 
 
KCa1.1 KCNMA1 Neurons 
and 
Glioma 
 Glioma  
KCa2.3 KCNN3 Breast    
KCa3.1 KCNN4 Glioma Vascular smooth 
muscle 
Glioma and 
Colon 
 
 
 
 
 
 
 
 
33 
 
CHAPTER 2 
 
POLYCOMB-DEPENDENT REPRESSION OF THE POTASSIUM CHANNEL-
ENCODING GENE KCNA5 PROMOTES CANCER CELL SURVIVAL UNDER 
CONDITIONS OF STRESS1 
 
Abstract 
Relapse after clinical remission remains a leading cause of cancer-
associated death. Although the mechanisms of tumor relapse are complex, the 
ability of cancer cells to survive physiologic stress is a prerequisite for 
recurrence. Ewing sarcoma (ES) and neuroblastoma (NB) are aggressive 
cancers that frequently relapse after initial remission. In addition, both tumors 
over-express the polycomb group (PcG) proteins BMI-1 and EZH2, which 
contribute to tumorigenicity. We have discovered that ES and NB resist hypoxic 
stress-induced death and that survival depends on PcG function. Epigenetic 
repression of developmental programs is the most well established cancer-
associated function of PcG proteins. However, we noted that voltage-gated 
potassium (Kv) channel genes are also targets of PcG regulation in stem cells. 
Given the role of potassium in regulating apoptosis, we reasoned that repression 
                                            
1 Ryland KE, Svoboda LK, Vesely ED, McIntyre JC, Zhang L, Martens JR, et al. 
Polycomb-dependent repression of the potassium channel-encoding gene 
KCNA5 promotes cancer cell survival under conditions of stress. Oncogene. 
2014. doi: 10.1038/onc.2014.384. 
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of Kv channel genes might play a role in cancer cell survival. Here, we describe 
our novel finding that PcG-dependent repression of the Kv1.5 channel gene, 
KCNA5, contributes to cancer cell survival under conditions of stress. We show 
that survival of cancer cells in stress is dependent upon suppression of Kv1.5 
channel function. The KCNA5 promoter is marked in cancer cells with PcG-
dependent chromatin repressive modifications that increase in hypoxia. Genetic 
and pharmacologic inhibition of BMI-1 and EZH2, respectively, restore KCNA5 
expression, which sensitizes cells to stress-induced death. In addition, ectopic 
expression of the Kv1.5 channel induces apoptotic cell death under conditions of 
hypoxia. These findings identify a novel role for PcG proteins in promoting cancer 
cell survival via repression of KCNA5. 
Introduction 
The ability to resist cell death is a hallmark of cancer (19). Cancer cells are 
able to survive despite exposure to cell intrinsic (e.g. metabolic and genotoxic) 
and extrinsic (e.g. hypoxia, nutrient deprivation) stress (19). This ability to survive 
conditions of stress allows cancer cells to escape physiologic death responses 
that are induced upon exposure to hostile microenvironments. In rapidly growing 
solid tumors the cancer outstrips its blood supply, thereby subjecting the cancer 
cells to a hostile microenvironment that is characterized by oxygen, growth factor 
and nutrient deprivation (19, 182). Furthermore, chemotherapy and radiation 
exacerbate the hostile local microenvironment by inducing tumor necrosis. 
Despite exposure to these tremendous stresses, however, solid tumors often 
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recur after clinical remission and relapse remains a leading cause of cancer-
associated death. The mechanisms of tumor relapse are both diverse and 
complex but elucidating how cancer cells resist stress-induced death has the 
potential to uncover novel opportunities for cancer therapy. 
Stem cells harbor the ability to self-renew indefinitely and are epigenetically 
programmed to resist differentiation and to survive in hypoxic niche environments 
(183). Tumor cells often hijack normal stem cell processes to support their 
propagation and this is particularly evident in cancer cell populations that display 
tumor-initiating properties (19, 184). Although the mechanisms that support 
maintenance of stem cell traits are complex (183), chromatin repressive 
complexes are essential mediators of stemness and also crucial contributors to 
cancer pathogenesis (185). Among the best characterized of the chromatin 
repressive complexes are the polycomb group protein complexes PRC1 and 
PRC2 (reviewed in (185) and (179)). Polycomb proteins function to silence target 
gene loci via direct post-translational modification of histones. In particular, the 
PRC1 complex proteins BMI-1 and RING1B cooperate to induce ubiquitination of 
histone 2A at lysine residue 119 (H2AubK119), while the PRC2 member EZH2 
mediates methylation of histone 3 at lysine residue 27 (H3K27me3) (185). 
Together these chromatin marks support maintenance of a repressed chromatin 
state that inhibits transcriptional activation (179). Both BMI-1 and EZH2 are 
highly over-expressed by many human cancers and play central roles in tumor 
initiation and tumor progression (179). In particular, over-expression of polycomb 
proteins is evident in tumor-initiating cell populations (186) and in the aggressive 
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pediatric solid tumors Ewing sarcoma (ES) and neuroblastoma (NB) (174-178). 
The precise targets of polycomb-dependent regulation are cell type and context 
specific but, in general, polycomb repressive complexes support maintenance of 
stemness and oncogenesis by suppressing the expression of tumor suppressor 
genes and developmental regulators (146, 179) 
Controlled regulation of intracellular levels of elemental ions is essential for 
normal cellular homeostasis. Transmembrane channels control ion flux across 
cellular membranes and there is abundant evidence that deregulation of calcium 
and sodium channel function can contribute to cancer pathogenesis in diverse 
fashions (187, 188). In addition, altered expression, regulation and function of 
potassium ion channels has been implicated in several cancer hallmarks 
including abnormal proliferation, resistance to cell death, and enhanced migration 
(7). In the current study we have identified the voltage-gated potassium channel 
Kv1.5-encoding gene, KCNA5, as a novel target of polycomb-dependent 
repression in aggressive cancer cells. Significantly, our studies show that 
epigenetic repression of KCNA5 contributes to selective survival of cancer cells 
under conditions of hypoxic stress and implicate activation of the Kv1.5 channel 
as a central mediator of hypoxia-induced apoptotic cell death. 
Experimental Procedures 
Cell Culture and Viability 
ES cells were cultured in RPMI-1640 media (Gibco, Grand Island, NY, 
USA) and NB cells in MEM 1x media (Gibco, Grand Island, NY, USA). Media 
was supplemented with 10% FBS (Atlas Biologicals, Inc., Fort Collins, CO, USA) 
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and 6 mM L-glutamine (Life Technologies, Grand Island, NY, USA). Identities 
were confirmed by short tandem repeat profiling. HuVEC cells were cultured in 
EBM-2 Basal Medium (Lonza, Pittsburgh, PA, USA) supplemented with EGM-2 
SingleQuot Kit Suppl. & Growth Factors (Lonza, Pittsburgh, PA, USA). HL-1 cells 
were cultured in Claycomb media (Sigma-Aldrich, St. Louis, MO, USA-Aldrich) 
supplemented in 10% FBS (Sigma-Aldrich, St. Louis, MO, USA-Aldrich), 2 mM L-
glutamine, 100 µg/mL Penicillin/Streptomycin and 0.1 mM Norepinephrine 
(Sigma-Aldrich, St. Louis, MO, USA-Aldrich). Cells were maintained in ambient 
conditions at 37°C in 5% CO2. For growth factor deprivation and hypoxia studies 
FBS was removed and cells were placed in 1% O2 in an xVivo system 
(Biospherix, Lacona, NY, USA). Viability was determined by cell counting and 
trypan blue. Data were normalized relative to 0 hours.   
Pharmacologic inhibitor studies 
4’Aminopyridine (4’AP) (50 µM, Sigma-Aldrich, St. Louis, MO, USA-
Aldrich) was prepared in an aqueous solution and diphenyl phosphine oxide-1 
(DPO-1) (310 nM, Tocris Bioscience, Bristol, UK) and GSK-126 (1 µM, 10 µM, 
Active Biochem, Maplewood, NJ, USA) were diluted in dimethyl sulfoxide 
(DMSO). Cells were pre-treated for 72 hours. 
Generation of genetically modified cells 
Cell lines were transduced with pLKO.1-puro vectors (Sigma-Aldrich, St. 
Louis, MO, USA-Aldrich) containing one of two short hairpin RNAs targeting BMI-
1 (shBMI-1#156: 5’- CCTAATACTTTCCAGATTGAT-3’ or shBMI-1 #157: 5’- 
CGGAAAGTAAACAAAGACAAA-3’) or a non-silencing control sequence (shNS: 
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5’-CAACAAGATGAAGAGCACCAA-3’). Cells were selected in puromycin (2 
µg/mL, Sigma-Aldrich, St. Louis, MO, USA-Aldrich) for 48 hours prior to 
experimentation. 
Adenoviral constructs were generated using pAD/V5/-dest (Invitrogen, Grand 
Island, NY, USA). Virus was produced using ViraPower (Invitrogen, Grand 
Island, NY, USA) and purified using ViraPur Adenovirus mini purification 
(ViraPur, San Diego, CA, USA). Cells were infected with Kv1.5-GFP-WT, KV1.5-
GFP-PD and soluble GFP 24 hour’s prior to use in an experiment. Response of 
the infected cells to hypoxia was tested by transferring cells to a 1% O2 chamber 
as above. 
Quantitative Real-Time PCR 
Total RNA extraction was performed using RNeasy® Plus Mini kit (Qiagen, 
Valencia, CA, USA) and cDNA generated using iScript (Bio-Rad, Hercules, CA, 
USA). qRT-PCR was performed using validated SYBR primers (sequences 
below). Analysis was performed in triplicate using the Lightcycler® 480 System 
(Roche Applied Science, Indianapolis, IN, USA). Data were analyzed by 
normalizing average Ct values of the gene of interest to the geometric mean of 
reference genes (HPRT and GAPDH) using ΔΔCt method. 
qRT-PCR Primers 
Primers Sequence (5’ to 3’) 
KCNA5 (Human) Forward: GTA ACG TCA AGG CCA AGA GC 
BMI-1 (Human) Forward: CGT GTA TTG TTC GTT ACC TGG A 
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KCNA5 (Mouse) Forward: CAG CGG GTC CTC ATA AAC AT 
 
Western Blot and Immunocytochemistry 
Levels of BMI-1 (Millipore, Mouse mAb #05-637, Billerica, MA), EZH2 (Cell 
Signaling Technology, Rabbit mAb #4905, Danvers, MA), or GAPDH (Cell 
Signaling Technology, Rabbit mAb #2118) were determined using standard 
western blot assays as previously described (189).  
For apoptosis studies TC-71 cells were treated with 4 µg Etoposide or infected 
with Kv1.5-WT, Kv1.5-PD or sGFP. After 24 hours, cells were placed in ambient 
(21% O2) or hypoxic (1% O2) conditions. After 8 hours, cells were fixed with 4% 
paraformaldehyde (10 min.), permeabilized with 0.1% Triton X-100 (10 min.) and 
blocked with 2% goat serum (20 min.). Cells were incubated with polyclonal anti-
cleaved capase-3 (1:200 dilution, Cell Signaling Technology, Rabbit mAb #9661) 
in 2% goat serum (45 min.), followed by incubation with goat anti-rabbit Alexa 
Fluor-594 antibody (1:200 dilution, Life Technologies, Grand Island, NY, USA, 
Grand Island, NY, USA) in 2% goat serum (40 min.). Nuclei were labeled with 
DAPI (Life Technologies, Grand Island, NY, USA, Grand Island, NY, USA) and 
mounted with ProLong Gold (Invitrogen, Grand Island, NY, USA, Grand Island, 
NY, USA). 
Cell images were acquired on a Nikon TI81 A1R confocal microscope with a 
60x by 1.40x N.A. oil objective. For every experiment 5-10 images were acquired 
for each condition and 50-100 cells were analyzed. Z-stack images were 
compiled with ImageJ software (NIH, Bethesda, MD). The resolution obtained in 
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these imaging experiments was 512 by 512 pixels with a z resolution of 0.5µm for 
each filter set. 
Electrophysiology 
The isolation and recording of the IKur current, specific current of the Kv1.5 
channel, was recorded by a whole-cell patch clamping protocol as previously 
described (190). Total potassium current was recorded using 10mV step 
depolarizations, from a holding potential of -80mV, to +60mV.  The intracellular 
pipette solution contained (in mM): KCl 148, MgCl2 1, EGTA 5, HEPES 5, K2ATP 
5; and was adjusted to pH 7.2 with KOH. The bath solution contained (in mM): 
NaCl 148, NaH2PO4  0.4, MgCl2 1, KCl  5.4, CaCl2 1, HEPES 15; and was 
adjusted to pH 7.4 with NaOH. 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) was 
performed using established protocols, with modifications. Cells were fixed with 
1% formaldehyde, lysed, and sonicated (Qsonica cup horn sonicator, 100% 
amplitude). DNA fragments were in the 200-700 bp range. The following 
antibodies were then added to the pre-cleared sample and incubated overnight at 
4°C: Anti-Trimethyl Histone H3Lys27 (Millipore 07-449, 2µg) and Anti-Ubiquityl-
Histone H2ALys119 D27C4 XP (Cell Signaling Technology #8240, 10µl).  The 
complexes were purified using protein-G dynabeads (Invitrogen, Grand Island, 
NY, USA) followed by elution and crosslink reversal. DNA was recovered using 
QIAquick PCR Purification Kit (Qiagen, Valenica, CA, USA).  Target sequences 
were amplified by PCR using iTaq SYBR green (Bio-Rad, Hercules, CA, USA). 
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Primer sequences for the KCNA5 promoter were KCNA5 #1 (Forward: 5’-
TCCAGCATCATCAGTTTCCA -3’ and Reverse: 5’- 
TGGCTCTCATTATGCACCAG-3’) and KCNA5 #2 (Forward: 5’-
GCTGAAGGTTGCATCTGCT-3’ and Reverse: 5’- GGCCCTGACGTCAAGAAG-
3’). Data were analyzed using the percent input method where  Percent input = 
100*2^(Average Ct Input – Average Ct IP).   
Statistical Analysis 
Statistics were performed using GraphPad Prism 6 (San Diego, CA, USA) 
and values of p<0.05 between groups were considered significant. 
Results 
Polycomb proteins promote cancer cell survival under conditions of 
hypoxic stress. Most pediatric solid tumors, including NB and ES, respond to 
chemotherapy and tumors exhibit extensive necrosis at the time of surgery. 
However, a significant number of patients relapse following initial clinical 
remission demonstrating that at least some cells are capable of surviving the 
stress of a necrotic microenvironment. In order to explore the potential 
mechanisms that underlie resistance to stress-induced death we studied non-
malignant and cancer cells in in vitro conditions that mimic the hostile 
microenvironment of a necrotic solid tumor. Specifically, cells were exposed to 
either ambient, unstressed conditions (21% oxygen, 10% FBS) or 
microenvironmental stress (1% oxygen, 0% FBS) and cell viability monitored 
over time. Exposure of non-malignant endothelial (HUVEC) and atrial (HL-1) cells 
to stress resulted in significant cell death that was evident within 24 hours and 
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increased over time (Figure 1.1A). In contrast, ES (Figure 1.1B) and NB (Figure 
1.1C) cells exhibited no significant loss of viability after up to 72 hours. Thus, 
these studies confirmed that ES and NB cells are relatively resistant to 
microenvironmental stress. 
NB and ES are highly undifferentiated tumors that are thought to arise from 
stem and progenitor cells of neural crest (NB, ES) and/or mesenchymal (ES) 
origin. Stem cells thrive in conditions of hypoxia, leading us to hypothesize that 
the ability of NB and ES to survive stress may be linked to their primitive stem-
like biology. Both ES and NB cells express high levels of the polycomb complex 
proteins BMI-1 and EZH2 and over-expression of these proteins contributes to 
stemness, tumorigenicity and tumor progression (174-178, 191). To test whether 
polycomb proteins contribute to survival of cancer cells under conditions of stress 
we evaluated viability in NB and ES cells that had been modified to down-
regulate polycomb function. First, we assessed survival of cells that had been 
engineered to down-regulate BMI-1 as a result of RNA interference (Figure 
S1.1A). Significantly, NB and ES cells with reduced levels of BMI-1 showed no 
change in viability in ambient conditions but died upon transfer to stress 
conditions (Figure 1.2A-B). Next, we used the pharmacologic inhibitor GSK-126 
to inhibit the methyltransferase activity of EZH2 (192). Once again, inhibition of 
polycomb function had no impact on cell survival under ambient conditions but 
resulted in loss of cell viability under conditions of stress (Figure 1.2C-D). Thus, 
survival of both ES and NB cells under conditions of hypoxia and nutrient 
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deprivation is, at least in part, dependent on the continued activity of the 
polycomb proteins BMI-1 and EZH2. 
KCNA5 is repressed by polycomb in cancer cells. Having established that 
polycomb proteins promote cancer cell survival under conditions of stress we 
next sought to define the mechanism underlying the death-resistant phenotype. 
Polycomb proteins repress thousands of gene loci in a highly context specific 
manner. In human embryonic stem cells they specifically bind the promoters of 
nearly 2,000 protein-encoding genes involved in orchestration of normal 
embryonic development (146). In addition, in stem cells, fibroblasts and cancer 
cells the most prevalent targets of polycomb regulation are transcription factors 
that instruct cell fate and organogenesis and genes that are known to function as 
tumor suppressors, such as the cell cycle inhibitor CDKN2A (31, 146, 179). 
However, we noted on further analysis of the published data that promoters of 
potassium ion channel genes were also discovered to be highly enriched 
(p<3.8x10-11) among directly bound polycomb targets in stem cells (See 
Supplementary Table 10 in (146)) and also figured prominently among polycomb-
regulated targets in human embryonic fibroblasts (See Supplementary Table 3 in 
(31)). Potassium flux out of a cell is a key requirement for apoptosis (8, 193) and, 
although altered expression of over 20 potassium ion channels has been 
described in human cancers, only two (Kv1.5 and Kv7.1) are down-regulated in 
tumors (7).  Significantly, BMI-1 dependent silencing of the KCNA5 gene, which 
encodes Kv1.5, was recently shown to promote ischemic tolerance in neurons 
(103). Thus, we hypothesized that tolerance of hypoxic stress in cancer cells 
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might be mediated by polycomb-dependent repression of the KCNA5 locus. To 
address this we first interrogated publicly available microarray databases to 
determine if expression of the KCNA5 transcript is altered in NB and ES. As 
shown in Figure 1.3A, basal levels of KCNA5 are reduced in both tumor types 
compared to non-malignant embryonic and adult tissues. In addition, levels of 
KCNA5 expression were found to be higher in a subset of ES tumors that did not 
express high levels of BMI-1 (194), thus providing indirect evidence that BMI-1 
might repress KCNA5 in ES (Figure 1.3B). Further support for this relationship 
was evidenced by an inverse relationship between BMI-1 and EZH2 expression 
and KCNA5 expression in primary NB tumors (Figure S1.1B). To directly assess 
whether KCNA5 is targeted for polycomb-mediated silencing in ES and NB, we 
performed chromatin immunoprecipitation (ChIP) experiments using antibodies to 
the polycomb-dependent histone modifications H2AubK119 and H3K27me3. 
H2A119ub is mediated by the BMI-1 partner protein RING1B and H3K27me3 by 
EZH2. In each of the cancer types we detected enrichment of both polycomb-
dependent modifications at the KCNA5 promoter, in particular H2A ubiquitination 
was highly enriched over background in both ES and NB cells (Figure 1.3C-D). 
Moreover, exposure of the cells to stress resulted in a near two-fold increase in 
the H2A119Ub mark demonstrating that the cells acutely respond to 
microenvironmental stress by further repressing the KCNA5 promoter (Figure 
1.3E). Consistent with polycomb-dependent repression of the locus in ES and NB 
cells, we detected little to no KCNA5 transcript in ambient conditions and no 
measurable increase was detected following exposure to stress (Figure 1.3F and 
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Figure S1.1C). In contrast, KCNA5 transcription was increased in BMI-1-
knockdown following transfer to stress conditions (Figure 1.3F) and EZH2 
inhibitor-treated cells (Figure S1.1D). Thus, the KCNA5 promoter is subject to 
epigenetic regulation by polycomb group proteins in ES and NB and persistent 
polycomb-dependent repression of the locus prevents up-regulation of the 
transcript when cells are exposed to microenvironmental stress. 
The Kv1.5 channel regulates hypoxic stress-induced cell death. After 
confirming that polycomb proteins epigenetically repress KCNA5 in ES and NB 
cells we next sought to define the functional consequences of this repression. 
Specifically, we wished to determine whether loss of Kv1.5 channel function 
contributes to cell survival under conditions of hypoxic stress. To address this we 
took advantage of the pharmacologic compound diphenyl phosphine oxide-1 
(DPO-1), a highly specific inhibitor of the Kv1.5 channel which effectively blocks 
potassium efflux through the channel with an IC50 = 310 nM (195) (Figure S1.2A). 
Non-malignant cells were exposed to DPO-1 and then transferred to stress 
conditions as above. Consistent with Kv1.5 being a key mediator of stress-
induced death, channel blockade using DPO-1 rescued cell viability in both 
HUVEC and HL-1 cells (Figure 1.4A). Viability of cells under ambient conditions 
was unaffected by channel blockade (Figure 1.4A). To confirm these results we 
next exposed cells to 4’aminopyridine (4’AP), another potent inhibitor of the 
Kv1.5 channel (IC50 = 50 µM) (135) (Figure S1.2A). Pharmacologic blockade of 
Kv1.5 using 4’AP also largely prevented death of stress-exposed HUVEC and 
HL-1 cells (Figure S1.2B). Thus, these findings indicate that hypoxic stress-
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induced death of non-malignant cells is, at least in part, dependent on a 
functional Kv1.5 channel. 
Next, we tested the impact of Kv1.5 channel blockade on cancer cells that had 
been sensitized to stress-induced death as a consequence of polycomb 
modulation. Significantly, exposure of BMI-1 knockdown cancer cells to DPO-1 
prevented stress-induced cell death (Figure 1.4B). Viability of ES cells was 
restored by DPO-1 while partial rescue was evident in the NB cells (Figure 1.4B). 
To test whether blockade of Kv1.5 would also restore the viability of EZH2-
inhbited cells we exposed GSK-126 treated cells to DPO-1 prior to transfer to 
stress conditions. As shown (Figure 1.4C), DPO-1 restored cell viability in GSK-
126 treated cells. Exposure of unmodified ES and NB cells to DPO-1 had no 
significant impact on cell death and cells remained viable in both ambient and 
stress conditions (Figure S1.2C). Together these data reveal the critical nature of 
polycomb proteins in promoting cancer cell viability under conditions of stress. In 
particular, they confirm that survival under conditions of hypoxic stress is, at least 
in part, dependent on polycomb-dependent suppression of the Kv1.5 channel. In 
addition, they further implicate both PRC1 and PRC2 in mediating epigenetic 
repression of the KCNA5 locus. 
Ectopic expression of Kv1.5 restores sensitivity of cancer cells to 
hypoxic stress-induced apoptosis. Potassium ion channels can affect cellular 
physiology through mechanisms that are both dependent or independent of their 
role as regulators of ion flux across the cell membrane (7) Having established 
that pharmacologic blockade of Kv1.5 prevents cell death under conditions of 
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stress, we next sought to more directly test if this effect on cell survival was 
mediated by blockade of potassium efflux. To address this question we 
transduced TC-71 ES cells with wild-type (WT) and non-conducting, pore-dead 
(PD) Kv1.5 mutant constructs or a control soluble GFP (sGFP) using adenoviral 
infection. Both Kv1.5 constructs carry full-length human KCNA5 cDNA, tagged in 
the extracellular loop with GFP, and the trafficking and biophysical properties of 
both WT and PD ectopic proteins recapitulate those of the endogenous channel 
(108, 196). However, unlike Kv1.5-WT, which is fully functional, Kv1.5-PD 
generates a non-functional channel that cannot conduct potassium across the 
cell membrane as a result of an amino acid change (W472F) within the pore 
region (Figure 1.5A) (196). Confocal microscopy confirmed successful infection 
of ES cells with all constructs and cytoplasmic membrane localization of both 
Kv1.5-WT and Kv1.5-PD proteins (Figure 1.5B). Whole cell patch clamp 
experiments confirmed the presence of a robust and functional channel in Kv1.5-
WT expressing cells and only background current in Kv1.5-PD that was 
equivalent to that of control sGFP infected cells (Figure 1.5C). To determine if the 
presence of ectopic channel altered cell viability we cultured infected cells in 
either room air (21% O2) or hypoxia (1% O2) for 24 hours. In these experiments, 
stress was limited to hypoxia alone without serum deprivation in order to more 
precisely assess the impact of channel re-expression on the hypoxic response. 
Expression of either Kv1.5-WT or Kv1.5-PD had no impact on cell viability in 
ambient conditions but transfer to hypoxic conditions resulted in death of the 
Kv1.5-WT cells (Figure 1.5D). In contrast, Kv1.5-PD cells experienced no loss of 
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viability in hypoxia (Figure 1.5D). To confirm that the hypoxia-associated death of 
Kv1.5-WT cells was due to efflux of potassium through the ectopic channel we 
exposed cells to DPO-1 and 4’AP. Significantly, survival of Kv1.5-WT cells in 
hypoxia was largely restored if cells were treated with either of the two 
compounds (Figure 1.5E). Finally, to test the specificity of Kv1.5 as a mediator of 
hypoxia-induced death we tested whether ectopic expression of two other 
voltage-gated potassium channels, Kv1.4 and Kv1.3, would mimic the effect of 
Kv1.5. In contrast to Kv1.5, ectopic expression of Kv1.4 and Kv1.3 induced no 
appreciable death in cells that were exposed to hypoxia (Figure S1.3A). After 24 
hours the Kv1.3 infected cells began to die but death was less than that of Kv1.5-
transduced cells and equivalent to that of cells that were infected with control 
vectors sGFP and Kv1.5-PD (Figure S1.3A, B). Kv1.4 infected remained viable at 
24 hours, suggesting that the lower titer of the Kv1.4 virus afforded protection 
against the non-specific adenoviral death that we observed with Kv1.5-PD, Kv1.3 
and sGFP infection (Figure S1.3A, B). Thus, these data demonstrate that the 
effects of Kv1.5 in mediating hypoxia-induced death are not generalizable to 
other Kv channels. 
Finally, we investigated the mechanism of cell death in Kv1.5 expressing cells. 
It has been previously shown that potassium efflux promotes caspase activation 
and apoptosis (5, 35). To determine if TC-71 cells expressing Kv1.5-WT protein 
were dying by apoptosis we assessed cleavage of caspase-3 in ambient and 
hypoxic conditions. Whereas Kv1.5-WT cells showed little evidence of caspase-3 
cleavage in ambient conditions, after 8 hours in hypoxia cells with cleaved 
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caspase-3 were readily detected (Figure 1.6A). By comparison, unmodified TC-
71 cells showed no evidence of caspase cleavage in either ambient or hypoxic 
conditions but apoptosis could be dramatically induced in both conditions by 
etoposide, a cytotoxic topoisomerase II inhibitor that is routinely used in ES 
therapeutic regimens (Figure 1.6B). By contrast, cells with cleaved caspase-3 
were only rarely detected in Kv1.5-PD and sGFP transduced populations in both 
ambient and hypoxic conditions (Figure 1.6C & D). Thus, these studies together 
demonstrate the specificity of Kv1.5 as a key mediator of hypoxia-associated cell 
death and confirm that, under conditions of cell stress, efflux of potassium 
through the channel promotes apoptotic cell death.  
Discussion 
Oxygen tension in normal tissues ranges from 2-9% but is often considerably 
less in stem cell niches and solid tumors (182). Normal sensing of oxygen 
tension is critical for cell proliferation and cell survival and cells that exist in 
hypoxic niches, such as cancer cells and stem cells, utilize sophisticated 
molecular tools to withstand the relatively ischemic microenvironment (183, 197-
199). Cell proliferation and survival are also intimately linked to the concentration 
of intracellular ions including potassium, sodium and calcium (5, 42, 48). In 
particular, high levels of intracellular potassium inhibit caspase activation and 
promote cell survival, revealing a role for potassium efflux in execution of 
apoptotic cell death (35, 40, 41). Intracellular potassium concentrations are 
controlled by transmembrane ion channels, which actively regulate the flux of 
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potassium ions through central pores (200, 201). There are 78 different 
potassium ion channels (7, 202) and each is expressed in a context specific 
manner and alters potassium flux in response to different cellular signals (200, 
201). Interestingly, recent studies of ion channel expression in cancer have 
suggested that deregulation of potassium channels is a characteristic of human 
tumors (reviewed in (7) and (49)). Moreover, recent high-throughput drug 
screening studies showed that the potassium ionophore salinomycin is 
selectively cytotoxic to cancer stem cell populations (203, 204). These findings 
together support further investigation of ion-channel targeted approaches as 
novel opportunities for cancer therapy. 
In the current study we have focused on defining the mechanism of Kv1.5 
channel suppression in aggressive pediatric solid tumors and the contribution of 
this suppression to tumor pathogenesis. Our results implicate polycomb-
dependent epigenetic repression of KCNA5 as a key mechanism of channel 
inhibition and reveal the critical role of this inhibition in promoting cancer cell 
survival under conditions of microenvironmental stress, in particular hypoxic 
stress. In addition, the inability of an ectopic pore-dead Kv1.5 channel to restore 
stress-induced death demonstrates that survival of Kv1.5 suppressed cancer 
cells is linked to its canonical function as a potassium conductor rather than to 
other potential non-canonical roles that might also impact on cell signaling (7) 
The Kv1.5 channel is a voltage-gated potassium channel that conducts 
potassium in response to changes in cell membrane potential (202). In addition, 
Kv1.5 is a putative oxygen sensor and contributes to the regulation of cell 
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proliferation and survival under conditions of hypoxia by altering intracellular 
potassium levels in response to shifts in redox states (1, 46, 83, 135, 205). The 
role of Kv1.5 as an oxygen-sensing channel is well established in both cardiac 
and pulmonary physiology and aberrant expression and regulation of Kv1.5 
channels contributes to pulmonary hypertension and cardiac arrhythmias (45, 46, 
97, 134, 205). It was recently shown that exposure of neuronal cells to acute 
hypoxia and glucose deprivation leads to apoptosis and that this ischemia-
induced cell death is associated with up-regulation of Kv1.5 expression (103). 
Significantly, tolerance to the ischemic insult could be elicited in this study if cells 
were first exposed to repetitive low-dose stress rather than an acute insult. At a 
molecular level this ischemic tolerance was found to be due to up-regulation of 
BMI-1 and recruitment of polycomb to the KCNA5 promoter (103). Thus, BMI-1 
dependent repression of the KCNA5 gene can be an adaptive, physiologic 
response to chronic stress. Our current studies reveal that, in BMI-1 over-
expressing cancer cells, this adaptive physiologic response has been co-opted to 
promote the survival of the cancer cells under conditions of acute stress. 
Whether this survival mechanism is an inherent feature of the cancer cell of 
origin (e.g. a stem cell) or an acquired characteristic that arises during the 
process of malignant transformation remains to be determined and will likely vary 
between different cancer types.  
There have been several reports that Kv1.5 expression is reduced in human 
cancers (6, 9, 12, 14, 15) and in gliomas loss of expression is directly correlated 
with tumor aggression, suggesting that loss of the channel might contribute to 
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tumor progression (11). Moreover, recent studies demonstrated that restoration 
of normal mitochondrial function and redox tension by use of the pyruvate 
dehydrogenase kinase (PDK) inhibitor dichloroacetate (DCA), resulted in de-
repression of KCNA5 transcription and induction of Kv1.5-dependent apoptosis 
(8). Unfortunately, although these initial findings suggested that DCA might be 
useful as a relatively non-toxic anti-cancer agent, later studies failed to show 
significant impact of DCA in other preclinical models (206). In particular, pediatric 
tumors including NB and ES were found to be completely insensitive to the 
cytotoxic effects of DCA (206, 207). Our discovery that the KCNA5 locus is 
targeted for polycomb-dependent repression in these tumors suggests that the 
disappointing results that have been encountered with DCA as an anti-cancer 
therapy may be due to the inaccessible chromatin state of the KCNA5 promoter 
in cancer cells that over-express BMI-1 and other polycomb proteins, such as 
pediatric solid tumor and cancer stem cells, 
In summary, we have identified that epigenetic repression of the KCNA5 gene 
by polycomb proteins, in particular BMI-1, inhibits Kv1.5 expression and function 
in ES and NB. These findings provide new evidence that the Kv1.5 cha1nnel 
plays a seminal role in execution of hypoxia-induced apoptotic cell death in 
aggressive cancers. In addition, they suggest that cancer cells hijack physiologic 
regulation of the Kv1.5 channel to promote their survival in hostile 
microenvironments. Future studies are now needed to determine how this 
knowledge about altered epigenetic regulation of KCNA5 can be therapeutically 
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exploited to maximize cell death in the context of aggressive solid tumors that are 
prone to relapse. 
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Figure 2.1. ES and NB cancer cells survive physiologic stress.  
Under conditions of stress (serum starvation + hypoxia) non-malignant HuVEC 
and HL-1 cells experience a significant reduction in cell viability (A). In contrast 
ES cells, TC-71 and A4573, (B) and NB cells, LA1-55N and SH-SY-5Y, (C) cells 
survive. ** p<0.005 (mean ± SEM, n=3). 
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Figure 2.2. Polycomb proteins promote survival of cancer cells under conditions 
of stress.  
Analysis of cell survival in control (shNS) and BMI-1 knockdown (shBMI-1) ES 
(A) and NB (B) cells after transfer to stress conditions shows loss of viability in 
shBMI-1 cells over a 72-hour time course. Exposure of ES cells, TC-71 and 
A4573, (C) and NB cells, LA1-55N and SH-SY-5Y, (D) to the EZH2 inhibitor 
GSK-126 at 1 µM and 10 µM for 72 hours results in loss of viability when cells 
are exposed to stress for 24 hours. * p<0.05, ** p<0.005 and *** p<0.001 (mean ± 
SEM, n=3) .   
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Figure 2.3. Polycomb group proteins repress KCNA5 in ES and NB cells.  
(A) Publicly available microarray data were analyzed using the R2: microarray 
analysis and visualization platform (http://r2.amc.nl). Expression of KCNA5 is 
significantly lower in ES (GSE34620) and NB (GSE16476) tumors compared to 
normal embryonic (GSE15744) and adult (GSE7307) tissues. (B) Expression of 
KCNA5 is increased in ES tumors that do not express high levels of BMI-1 
(GSE16016). * p<0.02 and *** p<0.001 (C) Site of PCR primers for evaluation of 
histone modifications at the KCNA5 promoter. (D) Chromatin 
immunoprecipitation-quantitative PCR (ChIP-qPCR) of ES and NB cells in 
ambient conditions shows enrichment of both H3K27me3 and H2AK119Ub 
marks at the KCNA5 promoter (relative to IgG control ChIP). (E) ChIP of ES and 
NB cells in ambient and stress conditions shows a near 2-fold increase in 
enrichment of H2AK119Ub at the KCNA5 promoter after exposure to stress. Data 
are from 2 independent experiments and are expressed as mean +/- SEM. (F) 
qRT-PCR analysis demonstrates significant upregulation of KCNA5 expression in 
BMI-1 knockdown ES and NB cells after 8 hours in stress conditions. Expression 
normalized to the geometric mean of HPRT and GAPDH in each sample and 
expressed as fold change in stress relative to ambient conditions. * p<0.05 by 
Mann-Whitney Test (mean ± SEM, n=3).  
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Figure 2.4. Stress-induced death is prevented by pharmacologic blockade of 
Kv1.5 channel function.  
Cell viability analysis demonstrates that treating cells with 310 nM DPO-1 largely 
prevents stress-induced death in non-malignant cells (A). Death is also 
prevented in cancer cells engineered to express reduced levels of BMI-1 (shBMI-
1) (B) and in cancer cells that have been exposed to 10 µM GSK-126 prior to 
transfer to stress conditions (C). Viability in ambient conditions is unchanged by 
exposure to 310 nM DPO-1. * p<0.05 and ** p<0.005 (mean ± SEM, n=3). 
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Figure 2.5. Ectopic expression of the Kv1.5 channel restores stress-induced 
death in ES cells.  
(A) Cartoon of the wild-type (Kv1.5-WT) and pore-dead (Kv1.5-PD) channels, 
depicting the amino acid change W472F which prevents efflux of potassium out 
of the Kv1.5 channel. (B) GFP-fluorescent immunocytochemistry and confocal 
microscopy reveals robust expression of ectopic Kv1.5-WT, Kv1.5-PD and 
soluble GFP (sGFP) in TC-71 cells 24 hours post adenoviral infection. (C) 
Electrophysiology confirms induction of functional Kv1.5 current in TC-71 cells 
transduced with Kv1.5-WT but not with Kv1.5-PD or sGFP. (D) TC-71 cells 
expressing Kv1.5-WT channel have a significant reduction in cell viability at 8 
and 24 hours in hypoxia while the TC-71 cells expressing the Kv1.5-PD channel 
are unaffected, in particular at 8 hours. (E) Pharmacological block of the Kv1.5 
channel with either 50 µM 4’AP or 310 nM DPO-1 largely prevents hypoxia-
induced death in Kv1.5-WT expressing ES cells. ** p<0.005 and *** p<0.001 
(mean± SEM, n=3).   
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Figure 2.6. The Kv1.5-WT channel mediates cell death through caspase-3 
activation.  
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(A) Immunocytochemistry and confocal microscopy of Kv1.5-WT expressing TC-
71 cells shows induction of caspase-3 cleavage in Kv1.5+ (GFP+) cells 
(Indicated by white arrows) following exposure to hypoxia. No significant 
cleavage is detected in Kv1.5+ cells in ambient conditions. (B) Cleaved caspase-
3 staining is not detected in parent TC-71 cells in either ambient or hypoxic 
conditions. To serve as a positive control for cleaved caspase-3 staining, cells 
were exposed to 4 µg Etoposide. This exposure resulted in robust induction of 
caspase-3 cleavage in both ambient and hypoxic conditions. Quantification of 
cells with cleaved caspase-3 is shown for cells in A & B, under ambient (C) (21% 
O2) and hypoxic (1%O2) (D) conditions. ** p<0.005 (mean ± SEM, n=2-3. 200-
400 cell nuclei were counted for each condition.). 
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Figure S2.1. Validation of BMI-1 knockdown cell lines and KCNA5 expression in 
GSK-126 treated ES and NB cells.  
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(A) Successful BMI-1 knockdown in TC-71 shBMI-1 and LA1-55N shBMI-1 was 
verified by qRT-PCR (top) and western blot analysis (bottom). (B) Publicly 
available microarray data were analyzed using the R2: microarray analysis and 
visualization platform (http://r2.amc.nl). Expression of KCNA5 is inversely 
correlated with both EZH2 and BMI-1 in NB tumors (GSE27608). (C) qRT-PCR 
analysis demonstrates TC-71 and LA1-55N lack KCNA5 expression in ambient 
and stressed conditions. (D) qRT-PCR analysis demonstrates an upregulation of 
KCNA5 expression in stress after pre-treatment with 10 µM GSK-126 in TC-71, 
A4573, LA1-55N and SH-SY-5Y cells. Expression was normalized to the 
geometric mean of housekeeping genes HPRT and GAPDH in each sample and 
expressed as fold change relative to scrambled control for BMI-1 knockdown 
cells and vehicle for GSK-126 treated cells. * p<0.05, ** p<0.005 and *** p<0.001 
(mean ± SEM, n=3). 
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Figure S2.2. Blocking Kv1.5 channel function with 4’AP prevents stress-induced 
death.  
(A) Chemical structures of 4’aminopyridine (4’AP) (left) and diphenyl phosphine 
oxide-1 (DPO-1) (right) obtained from the PubChem Compound database. (B) 
Cell viability graphs demonstrate that stress-induced death in HuVEC, HL-1 and 
TC-71 shBMI-1 cells are prevented by treating cells with 50 µM 4-AP. Treatment 
with 4’AP under ambient conditions has no toxic effect on any cell line. (C) 
Treatment with 310 nM DPO-1 under ambient and stressed conditions has no 
toxic effect on TC-71 or LA1-55N cell lines. * p<0.05 and *** p<0.001 (mean ± 
SEM, n=3). 
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Figure S2.3. The effects of other Kv channels, Kv1.4 and Kv1.3, and adenoviral 
infection on TC-71 cell viability.  
(A) TC-71 cells transduced with Kv1.4 or Kv1.3 adenoviral vectors remain viable 
in hypoxic conditions. (B) TC-71 cells transduced with 15 µL and 30 µL of sGFP 
have a marginal decrease in cell viability at 24 hours in hypoxia, demonstrating a 
non-specific effect of adenoviral infection on cell viability under conditions of 
stress. * p<0.05 (mean ± SEM, n=2-3). 
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CHAPTER 3 
 
THE KCNA5 PROMOTER IS HYPERMETHYLATED IN EWING SARCOMA 
AND SILENCING CONTRIBUTES TO CELL PROLIFERATION2 
 
Abstract 
Potassium channels regulate a variety of biological processes and 
dysfunction of these channels contributes to cancer initiation and progression. 
We recently showed that the KCNA5-encoded channel, Kv1.5, is a target of 
polycomb-group (PcG)–dependent repression in the aggressive pediatric solid 
tumor, Ewing Sarcoma (ES), and that this epigenetic silencing of the Kv1.5 
channel contributes to cell survival under hypoxic stress. In human cancer, the 
promoters of PcG target genes are often subject to aberrant DNA 
hypermethylation. Given that KCNA5 is a target of PcG mediated repression, we 
reasoned that this gene might also be a target of DNA hypermethylation.  Here, 
we describe our finding that the KCNA5 promoter is hypermethylated in ES and 
that inactivation of the Kv1.5 channel promotes cancer cell proliferation. We 
show that ES cancer cell proliferation is dependent on suppression of Kv1.5 
channel function. The KCNA5 promoter is marked by hypermethylation and 
                                            
2 Ryland KE, Hawkins AG, Weisenberger DJ, Borinstein SC, Laird PW, Martens 
JR and Lawlor ER. The KCNA5 Promoter is Hypermethylated in Ewing Sarcoma 
and Silencing Contributes to Cell Proliferation. Manuscript in Preparation.  
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pharmacologic inhibition of DNA methyltransferases reduces the methylation 
present at the promoter, restores KCNA5 transcript expression and slows ES cell 
proliferation. This work identifies DNA methylation as another epigenetic 
mechanism that regulates KCNA5 expression in cancer and further implicates 
epigenetic repression of the Kv1.5 potassium ion channel in tumor pathogenesis.  
Introduction 
A fundamental trait of cancer cells is their ability to sustain proliferation (19). 
Cancer cells accomplish this by hijacking and altering many pathways and 
silencing or mutating tumor suppressor genes involved in the regulation of cell 
proliferation (e.g. TP53 and pRB) (19). Importantly, the ability to sustain 
proliferative signaling is tied to another hallmark, resisting cell death, as cancer 
cells disable cell death circuitry to promote excessive cell expansion (19). 
Significantly, the proliferative phenotype of cancer cells contributes to relapse in 
numerous tumor types (e.g. breast cancer, melanoma, prostate cancer) (208-
210). Relapse is of particular importance in cancer treatment, especially in the 
pediatric solid tumor, Ewing Sarcoma (ES), as it remains a central issue and a 
leading cause of cancer-associated death (16, 17). Therefore, continuing to 
elucidate the mechanisms that promote cancer cell proliferation and cell 
expansion is key for developing novel anti-relapse therapies.     
In cancer, epigenetic gene inactivation is as common, if not more frequent 
than genetic mutations as a means of gene silencing and it significantly 
contributes towards the development of cancer ((211-214) and reviewed in (136, 
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215)). One epigenetic mark, DNA methylation, has gained significant attention in 
the cancer field over the last decade, due to the clinical applications of 
hypomethylating agents. DNA methylation occurs when DNA methyltransferase 
(DNMT) enzymes add a methyl group to the 5’ carbon position of a cytosine; this 
projects into the major groove of DNA and inhibits transcription (216). DNA 
methylation occurs at CpG islands, which typically reside in the promoter region 
of genes (217). The role of DNA methylation in mammalian cells is to maintain 
transcriptional silencing in regions of the genome. This mechanism is of 
importance, as DNA hypermethylation suppresses expression of harmful 
sequences that have over time integrated into the genome (e.g. viral sequences) 
(211, 216, 218). In cancer, DNA methylation is frequently used as a means to 
silence tumor suppressor genes that would otherwise function to inhibit 
tumorigenesis (e.g. VHL, MGMT, BRCA1, p16/CDKN2A) (214, 219, 220). In the 
aggressive pediatric cancer ES, a DNA methylation profile study identified that 
the genes subject to hypermethylation were those important for cell adhesion, 
cell cycle, cell regulation, development, transcription regulation and signal 
transduction (221). Therefore, continuing to elucidate the genes targeted by DNA 
methylation and understanding their biological significance, particularly in ES, 
can provide further support for clinical applicability of hypomethylating agents in 
ES cancer therapy.   
Potassium channels are transmembrane proteins that control cellular ionic 
homeostasis and are important for all cellular processes. Two key biologic 
processes in particular, cell proliferation and survival, are intimately linked to 
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intracellular potassium ion concentrations (5, 42, 48). As the cellular 
concentration of potassium ions is controlled by potassium channel expression 
and function, dysregulation of potassium channels can alter many biologic 
processes, including proliferation, migration and response to cell death triggers 
(7). Dysregulation of potassium channel expression has been identified in 
numerous cancers and recent studies suggest that this deregulation is a 
characteristic of cancer (7, 49). However, the mechanisms causing loss of 
controlled expression of potassium channels in cancer are currently not well 
understood. In the current study we have identified the voltage-gated potassium 
(Kv) channel Kv1.5-encoding gene, KCNA5, as a target of DNA methylation and 
epigenetic repression in ES. Our studies show that the repression of KCNA5 and 
inhibition of Kv1.5 channel activation, promotes ES cell proliferation.  
Experimental Procedures 
Cell Culture and Proliferation Assay 
The ES cell lines, TC-71, A673 A4573, were cultured in RPMI-1640 media 
(Gibco, 11875) and supplemented with 10% FBS (Atlas Biologicals, Inc., F-500-
A) and 6 mM L-glutamine (Life Technologies, 25030). Identities were confirmed 
by short tandem repeat profiling. Pellets of two non-transformed cell lines, 
HuVEC and MRC5, and five cancer cell lines, A549, LoVo, UM5, UM53 and 
U2OS, were collected for MethyLight studies. All cells were cultured in an 
incubator at 37°C in 5% CO2. For the proliferation studies, cells were plated at a 
density of 200,000 cells per 6-well plate and left for 24 hours prior to a 72-hour 
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course drug treatment where the cells were treated every 24 hours. Proliferation 
was determined by trypan-blue exclusion. 
Pharmacologic studies 
Diphenyl phosphine oxide-1 (DPO-1) (310 nM, Tocris Bioscience, 2533) 
was prepared in ethanol and 5-aza-2’-deoxycytidine (5’AZA-CdR, 100 nM, 
Sigma-Aldrich, A3656) was diluted in dimethyl sulfoxide (DMSO) (Fisher, D128-
500). Cells were pre-treated at these concentrations for 72-96 hours. 
Quantitative Real-Time PCR 
Total RNA extraction was performed using the RNeasy® Plus Mini kit 
(Qiagen) and cDNA was generated using iScript (Bio-Rad, BIO1708891). qRT-
PCR was performed using validated SYBR primers (KCNA5, GAPDH, HPRT;  
IDT). Analysis was performed in triplicate using the Lightcycler® 480 System 
(Roche Applied Science). Data were analyzed by normalizing average Ct values 
of the gene of interest (KCNA5) to the geometric mean of reference genes 
(HPRT and GAPDH) within each sample using ΔΔCt method.  
qRT-PCR Primers 
Primers Sequence (5’ to 3’) 
KCNA5 (Human) Forward: GTA ACG TCA AGG CCA AGA GC 
Reverse: TCC CAT TCC CTA CTC CAC TG 
 
Illumina GoldenGate® Methylation Array 
Initial assessment of KCNA5 methylation was interrogated on a previously 
custom-designed Illumina Golden-Gate bead array. This array consists of 1,536 
probes designed to detect DNA methylation at CpG islands within the promoters 
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of >1400 genes that are enriched for established targets of polycomb regulation 
in human embryonic stem cells (146). Two independent batches of samples were 
analyzed using this array, the first including 12 samples comprising 4 ES tumors, 
5 ES cell lines and 3 stem cell populations and the second comprised of 52 
samples from 11 different non-transformed adult tissues that were obtained at 
rapid autopsy (222). Analysis of methylation (as determined by beta values) was 
restricted to probes that were not targeted to promoters of X- or Y-linked genes 
and were successfully and reproducibly detected in over 75% of the samples in 
each experiment. This left a total of 1297 probes for analysis. A comparison of 
two groups was considered statistically significant if the difference in beta-values 
was ≥ 0.2 with an associated p-value <0.05 (2-tailed t-test).  
MethyLight Studies 
Initial MethyLight studies of Ewing Sarcoma tumor samples and cell lines 
were carried out by our collaborator Dr. Dan Weisenberger and Dr. Peter Laird 
using a previously described method (223). The Ewing sarcoma tumor samples 
analyzed in these studies were kindly provided by our collaborator Dr. Scott 
Borinstein. The later MethyLight studies involving decitabine were performed in 
the Lawlor laboratory. The process entailed, genomic DNA isolation using the 
Genomic DNA Clean & Concentrator Kit (Zymo Research, D4011). Sodium 
bisulfite conversion of genomic DNA was performed using EZ DNA Methylation 
Kit (Zymo Research, D5002). After sodium bisulfite conversion, the genomic 
DNA was amplified using MethyLight, a fluorescence-based real-time quantitative 
PCR, as previously described (223, 224). The primers and probes for KCNA5, 
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ALU-C4, and quality-control PCR reactions are listed below (IDT, Applied 
Biosystems and Biosearch Technologies). Control probes and conditions have 
been published previously (223). Analysis was performed in triplicate using the 
Lightcycler® 480 System (Roche Applied Science). Data was analyzed by 
calculating the average mean value from the Ct value using a standard curve 
generated by a dilution series of the positive control, fully methylated gDNA. 
Mean values were then used to find the average percentage of methylated 
reference (PMR) for each sample using the following formula: 100 x ((Average 
mean value of sample amplified with KCNA5 primers)/(Average mean value of 
sample amplified with ALUC4 primers))/((Average mean value of fully methylated 
gDNA amplified with KCNA5 primers)/(Average mean value of fully methylated 
gDNA amplified with ALUC4 primers)). This same method of analysis had been 
previously described (1).  
MethyLight Primers 
Primers Sequence (5’ to 3’) 
KCNA5 Forward: ATCGTAATCGGTTTAGTTTCGACG 
 Reverse: AATAAAAACGTATCTCGTCCGCG 
ALU-C4  
Forward: 
GGTTAGGTATAGTGGTTTATATTTGTAATTTTAGTA 
 Reverse: ATTAACTAAACTAATCTTAAACTCCTAACCTCA 
CONV-C1  Forward: AAATTGGAGATGAGGGATGGGT 
 Reverse: TTATCCTCCACTCATTCCCCAA 
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CONV-C2  Forward: AAATTGGAGATGAGGGATGGGT 
 Reverse:TTATCCTCCACTCATTCCCCAA 
CONV-C11  Forward: AAATTGGAGATGAGGGATGGGT 
 Reverse: TTATCCTCCACTCATTCCCCAA 
CONV-C16  Forward: AAATTGGAGATGAGGGATGGGT 
 Reverse: TTATCCTCCACTCATTCCCCAA 
CONV-C21 Forward: AAATTGGAGATGAGGGATGGGT 
 Reverse: TTATCCTCCACTCATTCCCCAA 
MethyLight Probes 
Probe Sequence (5’ to 3’) 
KCNA5 Probe 6FAM-CGTTAACCGACCTCCGCAAACGACC-BHQ1 
ALU-C4 Probe 6FAM-CCTACCTTAACCTCCC-MGBNGQ 
CONV-C1 Probe 6FAM-TCTTACAAACTAATCCTTAACTTT-MGBNFQ 
CONV-C2 Probe 6FAM-AACTGGTCCTTGGCTTT-MGBNFQ 
CONV-C11 
Probe 6FAM-TTACAAACTAGTCCTTGGCTTT-MGBNFQ 
CONV-C16 
Probe 6FAM-TTACAAACTAGTCCTTAGCTTT-MGBNFQ 
CONV-C21 
Probe 6FAM-TTACAAACTAATCCTTAGCTTT-MGBNFQ 
 
Statistical Analysis  
Statistics were performed using GraphPad Prism 6. Values of p<0.05 were 
considered significant. 
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Results  
The KCNA5 locus is hypermethylated in cancer. DNA methylation is a 
form of epigenetic regulation that is associated with gene silencing when 
methylation occurs in CpG islands of gene promoters. Cancer cells alter the 
epigenome and dysregulate DNA methylation patterns of genes, such that gene 
promoters become hypermethylated and intergenic regions become 
hypomethylated (136, 141, 211, 215). Interplay between DNA methylation and 
other epigenetic processes exist to heritably silence genes (147, 169, 170). 
Interestingly, in human cancer, the promoters of PcG target genes are often 
subject to aberrant DNA hypermethylation (225-227). Previous work from our 
group demonstrated that the KCNA5-encoded channel, Kv1.5, is a target of 
PcG–dependent repression in the aggressive pediatric solid tumors, Ewing 
Sarcoma (ES) and Neuroblastoma (NB). Furthermore, this epigenetic silencing of 
the Kv1.5 channel was shown to contribute to cancer cell survival under 
conditions of hypoxic stress (228). Therefore, we sought to determine whether 
the KCNA5 locus is hypermethylated in ES. To address this we assessed the 
DNA methylation status of the KCNA5 promoter by interrogating data from a 
custom Illumina GoldenGate® methylation array and by performing MethyLight 
studies. The GoldenGate® array analysis of ES cell lines and tumors and non-
transformed tissues shows that the KCNA5 promoter is hypermethylated in ES 
samples compared to non-transformed tissues, as the beta-values for the ES 
samples are significantly greater than the beta-values of the non-transformed 
tissues (Figure 3.1A). Collaborators, Dr. Peter Laird and Dr. Dan Weisenberger, 
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completed the initial MethyLight studies, while subsequent studies were 
completed in the Lawlor laboratory. By MethyLight analysis, we confirmed that 
the KCNA5 promoter is hypermethylated in ES samples, using an independent 
set of primary tumors and cell lines (Figure 3.1B). Furthermore, these studies 
demonstrate that the methylation of KCNA5 is relatively higher in ES cell lines 
than ES primary tumor samples (Figure 3.1B), potentially suggesting an adaptive 
mechanism for cancer cells to survive in culture. To compare the methylation 
status of KCNA5 to non-transformed cells, MethyLight analysis was conducted in 
the two non-transformed cell lines, HuVEC and MRC5. Similar to the 
GoldenGate® array data, methylation of KCNA5 is drastically lower in the two 
non-transformed cell lines compared to the ES cell lines and only slightly lower in 
comparison to the ES primary tumors (Figure 3.1B). Taking it a step further, we 
also analyzed the methylation profile of KCNA5 in mesenchymal stem cells 
(MSC), one of the putative stem cells for ES. Interestingly, we found that the 
methylation profile of KCNA5 in MSCs matched that found in the non-
transformed cells, with it being lower in comparison to the ES cell lines and 
primary tumors (Figure 3.1B). Next, we interrogated the degree to which KCNA5 
is methylated in other cancer cell lines. We discovered that in the aggressive 
cancer cell lines osteosarcoma (U2OS), non-small-cell-lung (A549), pancreatic 
(UM53) and adenocarcinoma cancer cells (LoVo), five out of six cell lines have 
high percentages of KCNA5 methylation (90-150% methylation) (Figure 3.1C). 
Interestingly, the pancreatic cancer cell line, UM5, a stem-like cancer cell line 
(personal communication from Simeone Laboratory), has a low percentage of 
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KCNA5 methylation (35-45%) (Figure 3.1C). Together, these studies 
demonstrate that DNA methylation is present at the KCNA5 locus in human 
cancer cells.  
Decitabine treatment results in loss of methylation at the KCNA5 
locus. Having established that DNA methylation epigenetically represses 
KCNA5; we next sought to determine if the KCNA5 locus could be demethylated 
using a hypomethylating agent. The hypomethylating agent chosen was 
decitabine, a nucleoside analog that inhibits DNMTs (229). Current research 
demonstrates that chronic exposure to epigenetic modifiers at sub-cytotoxic 
levels alters the epigenetic landscape in cancer cells (215, 230). Interestingly, 
decitabine treatment has a biphasic effect, such that at sub-cytotoxic levels it 
exerts a hypomethylating effect, while at high levels it has cytotoxic effects 
promoting cell death (231). Thus, we treated three ES cell lines over a course of 
72 or 96 hours with a sub-cytotoxic level of decitabine (100 nM). Exposure of ES 
cells to decitabine led to the demethylation of the KCNA5 locus in all three ES 
cell lines, TC-71, A673 and A4573 (Figure 3.2A). These studies confirm that 
exposure to 100 nM of decitabine hypomethylates the KCNA5 locus, partially 
restoring the epigenetic landscape of KCNA5 to that seen in non-transformed 
cells. Next, we investigated whether demethylation of the KCNA5 locus would 
lead to the upregulation of KCNA5 transcript. To address this, we performed 
qRT-PCR analysis of ES cells exposed to 100nM decitabine for 72 or 96 hours. 
We discovered that demethylation of the KCNA5 locus was associated with 
increased expression of the KCNA5 transcript in all three ES cell lines, TC-71, 
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A673 and A4573 (Figure 3.2B). Together, these studies confirm that the KCNA5 
promoter is subject to epigenetic regulation by DNA methylation in ES cells.  
Kv1.5 channel function inhibits ES cell proliferation. Understanding 
that decitabine treatment at sub-cytotoxic levels inhibits ES cell proliferation (173, 
232), we sought to replicate this effect in our own hands in three ES cell lines 
(TC-71, A673 and A4573). To test this, we conducted proliferation assays using 
a set number of ES cancer cells. Cells were either treated with no drug, vehicle 
(DMSO) or a sub-cytotoxic treatment of decitabine (100 nM) for 72 hours in 
ambient conditions (21% O2). Exposure of all three ES cells to decitabine 
resulted in significant decreases in cell proliferation compared to vehicle control 
(Figure 3.3A). Thus, ES cell proliferation in vitro is at least in part dependent on 
the activity of DNMTs and DNA methylation.  
Having established that decitabine treatment at sub-cytotoxic levels slows 
the proliferative rate of ES cells, we next sought to determine if the reduction in 
proliferation was mediated by restoration of Kv1.5 channel expression. To 
address this question we used the pharmacological compound diphenyl 
phosphine oxide-1 (DPO-1), a specific inhibitor of the Kv1.5 channel which 
blocks potassium efflux through the channel with an IC50 = 310 nM (195). 
Proliferation assays were repeated and ES cells (TC-71, A673, A4573) were 
exposed to DPO-1 and decitabine over a course of 72 hours. Blocking the Kv1.5 
channel with DPO-1 partially restores the proliferative phenotype of all three ES 
cell lines (Figure 3.3B). Importantly, the total number of dead cells across all 
conditions is largely consistent, demonstrating that a sub-cytotoxic level of 
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decitabine does not affect the viability of ES cells (Figure 3.3C, D). Lastly, 
exposure of ES cells to DPO-1 alone does not affect ES cell proliferation (Figure 
3.3E). Thus, these findings indicate that the Kv1.5 channel influences the 
proliferation of ES cells and potentially functions as a regulator of the cell-cycle in 
cancer cells.  
Discussion 
Potassium-conducting channels are essential, as they predominantly 
regulate and maintain resting membrane potential, an essential biophysical 
component of a cell (24). The membrane potential (Vm) of a cell functions as a 
biophysical signal, important for controlling many biological properties, such as 
proliferation, migration and differentiation (7, 24). Interestingly, as cells 
proliferate, their Vm changes due to alterations in potassium flux, which is 
caused by differential expression of potassium channels within the cell cycle (1, 
200, 233). The Vm of a cell is unique, because it regulates a cells progression 
through the cell cycle. Recent evidence has shown that cancer cells hijack the 
bioelectric regulator, the Vm, to be in a depolarized state by dysregulating 
potassium channel expression ((234) and see review (24)). These changes 
instruct the cancer cell to rapidly advance through cell cycle checkpoints, thereby 
sustaining proliferative signaling. Due to the diversity of potassium channels, 
identification of the key channels and the mechanisms regulating them have 
been slow, however it is clear that each channels contribution is cell-type and 
function specific (reviewed in (233, 235, 236)). Of the potassium channels, one of 
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prime interest is the Kv channel, Kv1.5, an important oxygen-sensitive channel, 
that has been implicated in mediating both apoptosis (8, 46, 83, 205) and cell 
cycle regulation (1, 133). In this study, we focused on an epigenetic mechanism 
regulating the Kv1.5 channel-encoding gene, KCNA5, and its impact on cell 
proliferation in ES.  
Cancer cells hijack and dysregulate epigenetic machinery to dynamically 
alter gene expression and drive tumor pathogenesis (136, 141). In ES, the PcG 
proteins, BMI-1 and EZH2, are induced and function as oncogenes contributing 
to ES tumorigenesis (175, 176). Previous work demonstrated that in ES, the 
KCNA5 promoter is targeted and repressed by BMI-1 and EZH2 (228). The 
consequence of PcG-dependent repression of KCNA5 is to promote ES cell 
survival under conditions of physiological stress, hypoxia (1% O2) and growth 
factor deprivation). In this study, we discovered that KCNA5 is also epigenetically 
silenced by DNA methylation. In particular, we determined that this locus is 
hypermethylated in cancer cells compared to non-transformed cells. Unlike PcG 
proteins, the importance of KCNA5 methylation is to promote cell proliferation 
under ambient conditions (21% O2 and growth factors). Together these studies 
suggest that the effect of KCNA5 expression on cancer biology is dependent on 
the epigenetic mechanism modulated. To specifically address this, future work 
will need to determine whether demethylation of the KCNA5 locus sensitizes 
cancer cells to physiological stress (hypoxia 1% O2 and growth-factor 
deprivation) and if this sensitization is dependent on Kv1.5 channel function. As 
recent advances have discovered the PcG protein, EZH2, recruits DNMTs to 
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establish a permanent repressive state in cancer cells (136, 237), future studies 
will also tease out the mechanistic crosstalk between DNMTs and PcG proteins 
at the KCNA5 locus in both ambient and stressed conditions. To accomplish this, 
we will use pharmacologic or genetic means to remove one epigenetic 
mechanism and determine its impact on the regulation of the KCNA5 locus by 
the other epigenetic mechanism using chromatin immunoprecipitation and 
MethyLight analyses. Lastly, our results reveal that demethylation of the KCNA5 
promoter leads to inhibition of ES cell proliferation. Therefore, this data suggests 
a role of the Kv1.5 channel in the modulation of cell-cycle progression in cancer 
cells.  
Cancer cells dysregulate potassium channels to promote proliferation, 
migration and differentiation (reviewed in (7)). Seminal work, demonstrated that 
Kv channels are the predominant channels involved in cell proliferation (238). 
Accumulating evidence demonstrates that the Kv1.5 channel is implicated in cell 
growth and proliferation (77, 132, 133, 239, 240). In myoblasts, high Kv1.5 
expression leads to accumulation of cyclin-dependent kinase inhibitors and 
impairs cell-cycle progression at the G1 to S transition, suggesting the channel to 
be a cell cycle checkpoint (133). As this channel is downregulated in numerous 
cancers (6, 9, 12, 14, 15) and inversely correlated to tumor aggression in 
gliomas, it suggests that downregulation of Kv1.5 contributes to tumor 
pathogenesis (11). Our studies begin to elucidate the role of the Kv1.5 channel in 
ES cell proliferation and the consequence of its downregulation. We discovered 
that the global hypomethylating agent, decitabine, directly promotes KCNA5 
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transcript and leads to a significant decrease in the proliferation of ES cells. 
Interestingly, we found that pharmacologically blocking the Kv1.5 channel 
partially restores the proliferative phenotype of ES cells. This study provides 
compelling evidence that potassium efflux through the Kv1.5 channel directly 
contributes to cancer cell proliferation. However, further studies are needed to 
investigate the role of the Kv1.5 channel in cancer cell proliferation and cell cycle 
regulation. To begin to address this, we will conduct another proliferation assay 
by trypan blue exclusion using another Kv1.5 channel blocker, 4’aminopyridine 
(4’AP). Next, an additional proliferation assay involving bromodeoxyuridine 
(BrdU) incorporation will be used to verify that the Kv1.5 channel activation 
inhibits ES cell proliferation.  Furthermore, to specifically determine if Kv1.5 
channel activation is affecting cell cycle progression, we will conduct cell cycle 
analysis using propidium iodine (PI) staining. Lastly, to directly determine if Kv1.5 
channel function affects ES cell proliferation, we will re-introduce the Kv1.5 
channel in ES cells using adenoviral constructs containing either the wild-type 
channel or the pore-dead channel, and conduct a proliferation assay by trypan 
blue exclusion. As the Kv1.5 channel contributes to membrane repolarization and 
resting membrane potential, it suggests that modulation of cell membrane 
polarization affects tumorigenesis. Thus, modulating membrane polarization 
through other ion channels (e.g. chloride) could re-capitulate the sensitization of 
cancer cells to physiological stress (24) and inhibit cell proliferation, as seen with 
Kv1.5. Ultimately, this could incorporate ion channel targeted therapies into 
cancer treatment.   
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In summary, we have identified another epigenetic mechanism, DNA 
methylation that contributes to the repression of the KCNA5 locus in cancer. This 
data provides additional evidence, that cancer cells hijack the physiological 
regulation of the Kv1.5 channel to promote tumorigenicity. Future work needs to 
elucidate how we can therapeutically exploit the epigenetic regulation of KCNA5, 
to eliminate aggressive cancers, such as ES, and prevent patient relapse.  
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Figure 3.1. The methylation status of KCNA5 in cancer cells.  
(A) Analysis of ES samples, consisting of 4 ES primary tumors and 5 ES cell 
lines, and 52 non-transformed tissue samples by a GoldenGate® assay 
demonstrates that in ES samples the KCNA5 promoter has a significantly higher 
level of methylation in comparison to non-transformed samples. *** p-value < 
0.001 and the difference beta-value ≥ 0.2 (mean ± SEM) between the two 
groups. (B) MethyLight analysis of 6 ES cell lines, 21 ES primary tumor samples, 
2 non-transformed cell lines (HuVEC, MRC5) and mesenchymal stem cells 
(MSC) reveals a broad range in the methylation of KCNA5. In particular, the ES 
cell lines have a diverse range in the methylation of KCNA5 and the mean 
percentage of methylation is higher compared to the ES primary tumors. As in 
(A) the non-transformed samples, HuVEC and MRC5, along with MSCs, have a 
lower percentage of KCNA5 methylation compared to ES samples. (C) 
MethyLight analysis of 6 other aggressive cancer cell lines, including 
osteosarcoma (U2OS), non-small-cell-lung (A549), pancreatic (UM53, UM5) and 
human colon adenocarcinoma (LoVo). Of the 6 cell lines, the UM5 cells have a 
low percentage of KCNA5 methylation (35-45%) in comparison to the 5 other cell 
lines that have a high amount of KCNA5 methylation (>100%). Data points are 
presented with mean values (n=2-3). Expression is presented as percent 
methylated reference (PMR).  
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Figure 3.2. Demethylation of the KCNA5 locus is associated with increased 
transcript expression.  
(A) MethyLight analysis demonstrates a significant decrease in the percentage of 
methylation at the KCNA5 promoter in TC-71, A4573 and A673 cells, after a 72-
hour treatment with 100 nM decitabine. Expression is presented as percent 
methylated reference (PMR). (B) qRT-PCR analysis demonstrates a significant 
upregulation of KCNA5 transcript expression in 3 ES cell lines (TC-71, A4573, 
A673) after a 72 hour treatment with 100 nM decitabine. Expression is 
normalized to the geometric mean of HPRT and GAPDH within each sample and 
the decitabine treated samples are represented as a fold change relative to the 
vehicle treated cells. * p<0.05 (mean ± SEM, n=3). 
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Figure 3.3. Blocking Kv1.5 channel function partially prevents the decitabine-
induced reduction in ES cell proliferation. 
(A) TC-71, A4573 and A673 cells have a significant reduction in cell proliferation, 
after a 72-hour treatment with 100 nM decitabine in ambient conditions. (B) Live 
cell count graphs demonstrate that blocking Kv1.5 channel function with 310 nM 
DPO-1 partially restores ES cell proliferation and therefore reverses the 
decitabine-induced reduction in cell proliferation. * p<0.05 (mean ± SEM, n=3). 
Dead cell count graphs demonstrate that treatment with 100 nM decitabine alone 
(C + D) and the combination of 100 nM decitabine and 310 nM DPO-1 (D) have 
no toxic effect on the ES cells. (E) Treatment with 310 nM DPO-1 under ambient 
conditions has no effect on TC-71, A4573 or A673 cell proliferation. 
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CHAPTER 4 
 
CONCLUSION 
 
Introduction 
The dysregulation of ion channels is an emerging field in cancer research 
(7, 13, 49). In particular, growing evidence suggests dysregulation of potassium 
channels directly impacts tumor progression (7, 49). However, as potassium 
channel expression and function is relatively unexplored in cancer, many gaps 
exist in our understanding of the mechanisms underlying their aberrant 
expression. Through the work of this thesis, we have discovered a novel 
mechanism underlying expression of the unique O2-sensitive channel, Kv1.5, in 
the pediatric solid tumors, ES and NB. Specifically, we have discovered that the 
epigenetic suppression of KCNA5 by the PcG proteins, BMI-1 and EZH2, and by 
DNA hypermethylation contributes to Kv1.5 channel and KCNA5 transcript 
downregulation (Illustrated in Figure 4.1). Furthermore, we determined PcG-
dependent suppression of KCNA5 is a mechanism by which cancer cells resist 
physiological stressors (i.e. hypoxia and growth factor deprivation) to promote 
cell survival, while the suppression of KCNA5 by DNA methylation promotes 
proliferative signaling. Importantly, this work determined that potassium efflux out 
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of the Kv1.5 channel is the trigger that drives apoptotic-mediated cell death and 
prevents cell proliferation. Therefore, this work provides further evidence that 
cancer cells manipulate intracellular potassium concentrations to promote tumor 
progression. To our knowledge, this work is the first to describe an epigenetic 
mechanism underlying the regulation of the potassium channel, Kv1.5, in human 
cancer. Overall, this thesis is significant because it provides a mechanism that 
can be therapeutically exploited to eliminate aggressive solid tumors prone to 
relapse.  
Implications for Cancer Pathogenesis and Future Biologic Study 
The Mitochondria and Dichloroacetate (DCA) 
Cancer cells dysregulate mitochondrial function to shift their energy 
metabolism to rely on glycolysis, as opposed to oxidative phosphorylation 
(Warburg effect) (241). This metabolic adaptation allows cancer cells to survive 
in a hypoxic microenvironment (242), increases their metastatic potential (242), 
offers a proliferative advantage (242) and induces resistance to apoptosis (8, 
243). As mitochondrial remodeling promotes tumorigenesis, reversing it may 
promote apoptosis, inhibit cell proliferation and reduce metastatic potential.  
Dichloroacetate (DCA) is a chemical modulator that selectively targets 
cells with abnormal mitochondrial function (8, 244). It was found to possess anti-
cancer properties due to its inhibition of cancer cell growth in a wide range of 
tumors (8, 206). In vitro studies discovered DCA induces apoptosis and inhibits 
proliferation of cancer cells and in vivo studies found DCA decreases metastases 
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and reduces tumor growth (8, 244-246). In addition, DCA has no effect on non-
cancerous cells, demonstrating its potential as a selective anti-cancer agent that 
possesses a low toxicity profile (8, 244). In a Phase I trial in patients with 
recurrent malignant brain tumors, such as Glioblastoma multiforme (GBM), 
(clinicaltrials.gov, NCT01111097), DCA was well tolerated at an individualized 
dose (247). The success of DCA in adult cancers, in the context of in vitro 
studies and a Phase I trial, led others to determine if DCA would have similar 
results in pediatric cancers. Regrettably, however, DCA was found to be 
completely ineffective at inducing apoptosis and inhibiting proliferation in six 
pediatric tumor cell lines, including ES and NB (207). Currently, the 
mechanism(s) preventing DCA from exerting its anti-cancer effect have not been 
addressed in these pediatric cancers.  
It is known that the Kv1.5 channel is intimately linked to the mitochondria 
through the mitochondria-ROS-HIF-Kv pathway (8, 101). The channel functions 
as the downstream trigger that mediates potassium efflux from the cell, which is 
critical for regulating apoptotic mediated cell death and proliferation (8, 101). 
Recent research elucidated in glioblastoma, non-small-cell-lung and breast 
cancers that DCA induces apoptosis through a Kv1.5-dependent mechanism (8). 
DCA treatment forces cancer cells to increase reliance on oxidative 
phosphorylation, which in turn increases production of ROS. Kv1.5 channels are 
then activated by ROS, which through a positive feedback loop involving removal 
of NFAT and de-repression of KCNA5, increases Kv1.5 channel expression and 
together induces caspase activation (8). It is known that the PcG protein, BMI-1, 
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is upregulated in ES and NB and in Chapter Two we demonstrate that BMI-1 
represses KCNA5 in ES and NB (228). Furthermore, BMI-1 is demonstrated to 
regulate mitochondrial function and redox balance (248-250). Together, this 
suggests that BMI-1 is a key element regulating cellular metabolism in cells. 
Therefore, we hypothesize that the dysregulation of BMI-1 in ES and NB cells 
prevents DCA treatment from having a biological effect. Furthermore, due to the 
direct repression of KCNA5 by BMI-1 in ES and NB, we also hypothesize that 
BMI-1 prevents DCA-mediated induction of KCNA5 transcript and the 
upregulation of Kv1.5 expression. Thus, if these hypotheses stand correct, then 
targeting and inhibiting BMI-1 would sensitize ES and NB to DCA treatment.  
To begin to address these hypotheses, we completed a few preliminary 
studies. First, to demonstrate that we could sensitize cells to DCA, we treated 
LoVo cells, a colon cancer cell line previously reported to be sensitive to DCA, 
with 20 and 40 mM of DCA for 48 hours (251, 252) (Figure 4.2A). After 
confirming that DCA treatment results in a decrease in LoVo cell proliferation, a 
phenotype previously described in the literature (251, 252), we moved on to 
determine whether BMI-1 prevents DCA from its anti-cancer effect in ES and NB. 
To address this, we utilized the BMI-1 knockdown ES cell line, TC-71 shBMI-1 
156, and its scrambled control, TC-71 shNS, and exposed these cells to either 
vehicle control (DMSO) or 10 mM DCA for 48 hours. We assessed both cell 
viability and cell proliferation by trypan blue exclusion. Interestingly, we 
discovered that BMI-1 knockdown cells have a significant decrease in cell 
proliferation when treated with DCA (Figure 4.2B). This provides preliminary 
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evidence that BMI-1 dysregulation does prevent DCA from having an effect in ES 
and potentially in NB. Taking it a step further, we utilized the TC-71 shNS and 
TC-71 shBMI-1 cells and the Kv1.5 specific blocker DPO-1, to determine if the 
DCA-induced proliferation inhibition is mediated by restoration of Kv1.5 channel 
function. We found that inhibition of the Kv1.5 channel partially restores cell 
proliferation in the TC-71 shBMI-1 cells (Figure 4.2B). These data provide 
preliminary evidence that the Kv1.5 channel regulates the DCA-induced effect on 
cell proliferation and implying that Kv1.5 channel expression is restored in the 
BMI-1 knockdown cells. Interestingly, these data describe the Kv1.5 channel 
mediating a proliferative phenotype associated with DCA, which is a novel 
finding, as the literature previously reports Kv1.5 mediating DCA-induced 
apoptosis (8). All together, these data point to BMI-1 as the key player in 
preventing the anti-cancer effects of DCA and Kv1.5 as the trigger in promoting 
DCA’s anti-cancer effect.  
Based on the promising data gathered from the preliminary studies, we 
will continue to elucidate the mechanism behind DCA insensitivity in ES and NB 
by focusing on the PcG protein, BMI-1 and the potassium channel, Kv1.5. The 
first set of experiments will determine whether BMI-1 prevents DCA from having 
an anti-cancer effect in other ES cell lines (A673, A4573) and in NB cell lines 
(LA1-55N, SH-SY-5Y). In these cell lines, we will utilize lentiviral constructs to 
knockdown BMI-1 and then expose the cells either to vehicle control (DMSO) or 
10 mM DCA. Cell proliferation will be assessed by trypan blue exclusion. As with 
the TC-71 shBMI-1 cell line (Figure 4.2B), we predict that the additional BMI-1 
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knockdown ES and NB cell lines will also have a significant decrease in 
proliferation upon DCA treatment. Taking it a step further, we will also determine 
if the DCA-induced reduction in proliferation is mediated by restoration of Kv1.5 
channel function. To accomplish this, we will expose the BMI-1 knockdown cells 
to DCA and the Kv1.5 blocker, DPO-1. We predict that inhibition of the Kv1.5 
channel will partially restore the proliferative phenotype in the other ES and NB 
cell lines, as seen in the TC-71 shBMI-1 cell line. Combined these experiments, if 
correct, will provide concrete evidence that BMI-1 is a key player in preventing 
the anti-cancer effects of DCA.  
Previously, we hypothesized that direct repression of KCNA5 by BMI-1 
prevents DCA-induced upregulation of the KCNA5 transcript. Therefore, we will 
determine if exposure of BMI-1 knockdown ES and NB cells to DCA upregulates 
KCNA5 transcript by qRT-PCR. We predict that in the BMI-1 knockdown cells, 
KCNA5 transcript will be detected, but only in the cells treated with DCA. If this 
holds true, then it suggests the effect of DCA works through a Kv1.5-dependent 
mechanism. To verify this, we will conduct an experiment that directly determines 
if the Kv1.5 channel and its potassium flux mediate the DCA-induced reduction in 
cell proliferation. In this study, we will ectopically express the Kv1.5 channel in 
ES and NB cells and then expose them to vehicle control or 10 mM DCA. Cell 
proliferation will be analyzed by trypan blue exclusion. In this experiment, two 
Kv1.5 channel constructs will be expressed, either Kv1.5 Wild-Type (functional 
channel) or Kv1.5 Pore-Dead (non-functional channel), to specifically determine if 
it is the flux of potassium out of the channel that affects cell proliferation. Based 
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on our preliminary data (Figure 4.2B), we hypothesize that the efflux of 
potassium out of the Kv1.5 channel mediates the DCA-induced reduction in 
proliferation. Therefore, we predict that only the cells expressing functional wild-
type Kv1.5 channel and treated with DCA will have a reduction in proliferation. So 
far, if all of our combined hypotheses stand correct, it would provide rationale for 
a combination treatment in ES and NB involving either the inhibition of BMI-1 or 
the ectopic expression of Kv1.5 followed by DCA treatment.  
DCA selectively targets the mitochondria (8, 244) and BMI-1 is 
demonstrated to have a role in mitochondrial regulation and redox homeostasis 
(248-250). Therefore, it can be suggested that BMI-1 exerts control over 
mitochondrial regulation and ROS generation and this contributes to the inability 
of DCA to exert an effect in ES and NB. To determine this, we will assess 
whether BMI-1 plays a role in regulating ROS generation and mitochondrial 
membrane polarization in ES and NB cells. Based on the literature, we 
hypothesize that BMI-1 overexpression in NB and ES contributes to the 
suppression of ROS and the hyperpolarization of the mitochondrial membrane. 
To address this, we will knockdown BMI-1 in ES and NB cell lines and measure 
ROS levels using an Amplex Red® assay and determine mitochondrial 
membrane polarization using the JC-1 MitoProbe™ Assay. We predict that in the 
BMI-1 knockdown cell lines there will be a significant increase in ROS generation 
and a depolarization of the mitochondrial membrane. Together, these studies 
would provide important mechanistic insight that could contribute to the rationale 
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for developing therapeutic strategies to target BMI-1 and ultimately incorporate 
DCA as a therapeutic treatment avenue in ES and NB.   
The proposed studies discussed so far focus on BMI-1 and its role in DCA 
treatment, however we are also interested in EZH2, the other PcG protein that is 
upregulated in ES and NB and represses the KCNA5 locus (see Chapter 2). As 
with BMI-1, we will determine if EZH2 contributes to the inability of DCA from 
exerting an effect in ES and NB cells and if this is due to repression of KCNA5 by 
EZH2. Based on the role of EZH2 in regulating KCNA5, as demonstrated in 
Chapter 2, we hypothesize that loss of EZH2 will sensitize ES and NB cells to 
DCA and it will be partially mediated through Kv1.5 channel function. To address 
this hypothesis, we will inhibit EZH2 by pre-treating ES and NB cells with GSK-
126 (an EZH2 inhibitor) and then exposure the cells to either 10 mM DCA or 10 
mM DCA and the Kv1.5 blocker, DPO-1. We will then conduct a cell proliferation 
assay using trypan blue exclusion. We predict that the cells treated with GSK-
126 and DCA will have a reduction in cell proliferation and this will be partially 
reversed by Kv1.5 channel inhibition. If this outcome occurs, it suggests that 
modulation of either EZH2 or BMI-1 is sufficient to promote Kv1.5 channel 
expression and sensitize ES and NB cells to DCA. Furthermore, this outcome 
could lead to the investigation of a potential cooperative mechanism between 
EZH2 and BMI-1 and its effect on DCA treatment. If however, we find that 
inhibition of EZH2 does not sensitize cells to DCA, then we will conclude that 
BMI-1 is the central PcG component regulating this effect.  
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KCNA5 is repressed by BMI-1, EZH2 and DNA hypermethylation in ES 
and NB and as we have discussed the contribution of BMI-1 and EZH2 towards 
the ineffective nature of DCA treatment, we will turn our attention to DNA 
methylation. To re-iterate, we hypothesize that it is the epigenetic repression of 
KCNA5 that prevents the anti-cancer effect of DCA in ES and NB. Therefore, we 
would like to determine if a reduction in the hypermethylation of KCNA5 would 
sensitize ES and NB cells to DCA and if this effect is mediated through the Kv1.5 
channel. To address this we will utilize decitabine, which at sub-cytotoxic doses 
(100 nM) has a hypomethylating effect. We will pre-treat ES and NB cells with 
decitabine, expose them to 10 mM DCA or 10 mM DCA and 310 nM DPO-1 and 
then conduct a cell proliferation assay. Similar to the other sections, we predict 
that the cells pre-treated with decitabine will be sensitized to DCA and this 
sensitization will be reversed in the DPO-1 treated cells. If this occurs, there is 
also the potential that inhibition of BMI-1 or EZH2 and DNA methylation could 
further increase the sensitization of ES and NB cells to DCA. Together this would 
provide multiple combination treatments (GSK-126 and DCA or decitabine and 
DCA), to sensitize ES and NB cells to DCA. However, if pre-treatment with 
decitabine has no effect then as mentioned in the previous paragraph we will 
conclude that BMI-1 is the central component regulating the DCA effect.  
In summary, our preliminary work and future studies suggest with 
modulation of BMI-1, EZH2, DNA hypermethylation and/or Kv1.5, DCA stands as 
a promising anti-cancer treatment in primary or recurrent ES and NB.  
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Ion Channel Therapy 
Potassium channels are cell-surface proteins that are accessible drug 
targets and have significant potential in disease states that aberrantly regulate 
their expression. Currently, potassium channels (e.g. Kv11.1 (HERG)) are 
successful drug targets in treating numerous diseases, including diabetes, 
hypertension and cardiac arrhythmias (49, 253, 254). As potassium channel 
expression is dysregulated in cancer, they could serve as useful drug targets in 
the treatment of cancer. 
The Kv1.5 channel is one of two potassium channels that are 
downregulated in cancer (Kv1.5 and Kv7.1). This thesis and other work (7, 8, 10, 
228) demonstrate that cancer cells downregulate the Kv1.5 channel in order to 
modulated its physiologic effects, such as promoting cell death and inhibiting cell 
proliferation, that inherently suppress cancer. Therefore, a novel therapeutic 
approach could be to develop tools that result in increased expression of Kv1.5, 
in cancer. Such methods that could be utilized include epigenetic modifiers (see 
Therapeutic Implications for Epigenetic Modifiers) or a novel way of delivering the 
channel directly to tumors (e.g. gene therapy). The clinical success of 
immunotherapy, oncolytic virotherapy and gene transfer has brought back the 
possibility of gene therapy as a potential treatment strategy in cancer (255). 
Therefore, as we aim to promote overexpression of the Kv1.5 channel in cancer, 
this could be accomplished through the use of gene therapy. In 2013, 
neurosurgeons at UCSD were able to utilize MRI guidance for the delivery of 
gene therapy (TOCA 511) as treatment for GBM in combination with 
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chemotherapy (https://health.ucsd.edu). In this study, which has now become a 
clinical trial, they used the TOCA 511 retrovirus to make tumors more susceptible 
to cancer killing drugs (clinicaltrials.gov, NCT01156584). This study opens up the 
possibility of engineering a gene therapy treatment aimed to overexpress the 
Kv1.5 channel, which could then be specifically injected  into the core of an ES or 
NB tumor. We hypothesize that overexpression of the Kv1.5 channel within a 
tumor would increase the sensitivity of cancer cells to standard treatment (and 
also to tumor hypoxia) and result in significant cell death and a decrease in tumor 
size. To test this hypothesis, we could utilize a patient derived xenograft (PDX) 
ES mouse model (256) or the MYC-N driven NB mouse model (257), and using 
MRI guidance inject a viral vector engineered to overexpress the Kv1.5 channel, 
into the core of these tumors. These mice would then be exposed to standard 
chemotherapy agents specific for ES or NB and during this time we would 
monitor tumor size and analyze the tumors for markers of cell death (e.g. 
necrosis and apoptosis). These measures would allow us to determine if Kv1.5 
channel expression in combination with standard treatment had a greater tumor 
suppressive impact than in the control mice exposed to chemotherapy alone. In 
conclusion, regardless of the method, expression of the Kv1.5 channel in cancer 
cells could be of great therapeutic value, particularly if paired with therapeutic 
agents, such as DCA or  with chemotherapeutic agents or radiotherapy, since re-
establishment of potassium efflux would be expected to sensitize cancer cells to 
oxidative, chemical and/or radiation stress. 
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Other potassium channels that could serve as targets in cancer would be 
those that are overexpressed and contribute to tumor pathogenesis as illustrated 
in Table 1 (Chapter 1). Currently, Kv10.1 (EAG1) is an appealing candidate as it 
is overexpressed in 70% of human cancers and its overexpression confers 
tumorigenic potential (258, 259). Preliminary work has demonstrated that 
inhibition of EAG1 by the small molecule blockers imipramine and astemizole is 
effective in reducing EAG1-driven cancer cell growth in vivo (260, 261). 
Furthermore, targeting channels like Kv10.1 in cancer could allow for re-
purposing of existing therapeutic agents. This would be beneficial for two 
reasons: first, it does not require development of new compounds and second, 
any undesired side effects could be accurately predicted based on their use in 
other diseases.  
 The importance of targeting potassium dysregulation in cancer is also 
demonstrated with the potassium ionophore salinomycin. In cancer research, 
salinomycin has been shown to selectively target a subpopulation of cancer cells, 
known as cancer stem cells (CSCs) in some types of cancers (e.g. breast (203), 
lung (262), colorectal (263) and leukemia (264)). Salinomycin exerts its anti-
cancer effect by interfering with transmembrane potential and promoting 
significant potassium efflux from the CSCs, resulting in apoptosis and an 
inhibition of proliferation (203, 265, 266). Prior studies have demonstrated a 
direct link between potassium efflux and the induction of apoptosis and 
cytotoxicity in cancer cells (36, 267). Together, these data demonstrate the 
therapeutic impact of manipulating potassium in cancer cells and provides 
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rationale for the use of salinomycin in cancer treatment. However, as salinomycin 
treatment would affect cancerous and non-cancerous cells alike, it would have to 
be aimed at cancer cells directly. A potential method of delivery is nanocarrier, 
which have been shown to increase tumor accumulation of small molecular drugs 
as they can specifically target tumors through tumor specific recognition 
molecules (e.g. epidermal growth factor) (268-271).  
The role of potassium channels in cancer biology is still an emerging field 
and drugs that target potassium channels are yet to be developed successfully. 
However, current studies can begin to design appropriate targets by elucidating 
the mechanistic function of potassium channels in cancer biology from in vitro 
and in vivo standpoints. 
Cancer Stem Cells (CSCs) 
CSCs are a specialized subpopulation of cells, possessing stem-like 
properties, which have emerged as a driving force behind tumor growth and 
recurrence (203, 272). According to the CSC hypothesis, CSCs possess the 
ability to reform a tumor (known as tumorigenicity) (273, 274). Furthermore, 
CSCs regenerate biologically heterogeneous tumors, consisting of CSCs and 
non-tumorigenic bulk tumor cells, therefore demonstrating the existence of cell 
hierarchy within a tumor (275). The CSC hypothesis has been demonstrated in 
numerous adult cancers (e.g. breast cancer, glioma, melanoma), as the CSC 
population in each tumor type is shown to reform tumors and re-establish 
hierarchical cell organization (273, 276-281). In contrast to adult tumors, CSCs 
have been isolated in relatively few pediatric tumors (282). Of those tumors, CSC 
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populations have been identified in both ES and NB (283, 284). Though, follow-
up studies demonstrate that within both solid tumors, CSCs are isolated in only a 
small fraction of the tumors analyzed (285, 286).   
A major concern with CSCs is their resistance to available therapy, 
consisting of chemotherapy and radiation (280, 287-291). Therefore, to prevent 
cancer relapse we need to develop strategies to increase the sensitivity of CSCs 
to current treatment. To accomplish this task, the mechanisms governing the 
maintenance of the CSC state need to be elucidated and exploited. One such 
mechanism could be the epigenetic regulation of the potassium channel, Kv1.5. 
As this was discovered and elucidated in pediatric tumors that innately possess 
stem-like properties, this mechanism could be applicable to adult cancers in the 
context of CSCs.  
We are interested in the role and regulation of potassium channels, 
specifically the Kv1.5 channel, in CSCs. To date, only one channel, the Kv11.1 
(HERG) channel, has been identified in CSCs, though its function is unknown 
(292). Furthermore, research with salinomycin, a potassium ionophore, 
demonstrates that potassium flux is important in CSCs, as significant potassium 
efflux from CSCs results in apoptosis and a decrease in proliferation (203, 265). 
In normal stem cells, it is known that potassium channels have a heterogeneous 
expression and their role is to regulate bioelectrical signals within the cell 
membrane (293). Of the potassium channels, the Kv channel family is important 
for controlling stem cell proliferation, specifically at the G0 and G1 checkpoints 
(293). Though the regulation of Kv channels in stem cells is unclear, it is known 
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that they are targets of PcG proteins (146, 228). Together, it can be suggested 
that potassium channels have an important function in stem cells and CSCs, as 
the salinomycin data suggests CSCs dysregulate potassium channel expression 
to promote tumorigenic potential. As our interest lies with the Kv1.5 channel, 
future work will focus on the regulation of the Kv1.5 channel encoding gene, 
KCNA5, and its biological impact on CSCs. In these studies we will utilize breast 
cancer cell lines (i.e. MCF-7, MDA-MB-231) to isolate CSCs, as they are well-
established model cell lines for CSC isolation.  
In this thesis, we discovered that KCNA5 is epigenetically repressed in ES 
and NB, therefore we hypothesize that epigenetic repression of the KCNA5 locus 
is an inherent feature in CSCs. To begin, we will assess the expression profile of 
KCNA5 transcript in CSCs using qRT-PCR, to establish that KCNA5 expression 
is silenced in these cells. If KCNA5 transcript is undetectable, we will determine if 
the PcG proteins, BMI-1 and EZH2, and DNA hypermethylation epigenetically 
repress the KCNA5 locus. To accomplish this we will perform ChIP experiments 
for the two PcG proteins, BMI-1 and EZH2, along with their histone modifications, 
H2AK119Ub1 and H3K27me3, and MethyLight studies to determine the 
methylation status of KCNA5. In these studies, the results for CSCs will be 
compared to bulk tumor cells, therefore we will also determine if there are any 
differences in the epigenetic regulation of KCNA5 in bulk tumor cells compared 
CSCs. As we hypothesize that the CSC population has similar properties to ES 
and NB cells, we predict that the degree to which KCNA5 is epigenetically 
repressed will be significantly higher in CSCs compared to bulk tumor cells. The 
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predicted difference in the epigenetic repression of KCNA5 could be an 
underlying mechanism contributing to the tumorigenicity of CSCs, in regards to 
cell survival and proliferation.  
In Chapters Two and Three we demonstrate that the epigenetic repression 
of KCNA5 promotes cancer cell survival and cell proliferation. Therefore, we 
hypothesize that the epigenetic repression of KCNA5 in CSCs promotes cell 
survival and proliferative signaling. To address this hypothesis, we will express 
the Kv1.5 channel in CSCs and assess its affect on cell viability and proliferation. 
Expression of the Kv1.5 channel in CSCs will be achieved through two methods.   
The first method will utilize genetic and pharmacologic reagents to inhibit the 
proteins contributing to the epigenetic repression of KCNA5, thereby allowing for 
expression of the KCNA5 transcript and the Kv1.5 channel. The second method 
will utilize adenoviral constructs to ectopically express functional and pore-dead 
versions of the Kv1.5 channel. Use of the Kv1.5 pore-dead channel is of 
particular importance, as it will inform us of whether it is the efflux of potassium 
out of the Kv1.5 channel that mediates CSC survival and proliferation. After 
expressing the Kv1.5 channel, CSCs will either be placed under conditions of 
stress, consisting of hypoxia and growth factor deprivation, or left in ambient 
conditions. The effect of the Kv1.5 channel on cell viability and cell proliferation 
will be determined by trypan blue exclusion. Based on the data in Chapters Two 
and Three, we hypothesize that expression of functional Kv1.5 channel will 
trigger CSC death under conditions of stress and slow the proliferation of CSC 
under ambient conditions. Together, the studies addressing the epigenetic 
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regulation of KCNA5 and its impact on CSC biology could provide concrete 
evidence that CSCs dysregulate Kv1.5 to promote tumorigenicity and a potential 
therapeutically exploitable mechanism.   
As previously mentioned, developing ways of therapeutically targeting 
CSCs is key in preventing tumor recurrence. Therefore we will determine if 
silencing of the KCNA5 locus contributes to the resilient nature of CSCs to 
current therapeutic agents. We hypothesize that expression of the Kv1.5 channel 
will sensitize CSCs to chemotherapeutic reagents. To address this hypothesis, 
the two methods, as previously described, will be employed to express the Kv1.5 
channel in CSCs. After expressing Kv1.5 in CSCs, the cells will be exposed to 
various chemotherapeutic agents often used in breast cancer treatment (e.g. 
doxorubicin and paclitaxel) at increasing concentrations (0.1 µM – 60 µM) and 
cell viability will be assessed using trypan blue exclusion. If expression of 
functional Kv1.5 channel sensitizes CSCs to chemotherapeutic agents, it could 
mean the discovery of a new therapeutic avenue in targeting CSCs either 
through the use of epigenetic modifiers (discussed below) or ion channel therapy.  
Suppression of KCNA5: A Consequence of Tumor Relapse or Cancer 
Transformation? 
The proposed studies for investigating the role of KCNA5 in CSCs brings 
up the question of whether the suppression of KCNA5 is associated with tumor 
relapse or a consequence of cancer transformation in ES and NB. As either 
outcome is plausible, we will conduct experiments testing both possibilities.  
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First, we will determine if the repression of KCNA5 is a consequence of 
tumor relapse by analyzing pre-existing clinical data from ES and NB patients. In 
this analysis, we will compare the expression profile of KCNA5 in relapsed 
patients versus patients upon initial diagnosis. This correlative clinical data would 
provide indirect evidence as to whether KCNA5 expression is further repressed 
in relapsed patients. On a side note, in this analysis, we could also determine if 
KCNA5 would serve as a predictive biomarker for response to standard 
treatment and/or survival outcome. To experimentally determine whether KCNA5 
is repressed in relapsed ES and NB cells, we will take in vitro and in vivo models 
of relapse for both ES and NB and analyze the expression profile of KCNA5. In 
the in vitro model, we will select and expand an ES and a NB cell population that 
became resistant to a chemotherapy agent (e.g. doxorubicin) and analyze 
KCNA5 transcript expression. With the in vivo model, we will take relapsed ES 
and NB tumors from mice and analyze them for KCNA5 transcript by quantitative 
real-time PCR and in situ hybridization. Assuming the in vitro and in vivo relapse 
models exist, these experiments would provide sufficient evidence for us to 
determine whether KCNA5 suppression is a consequence of tumor relapse.  
Next, to assess whether repression of KCNA5 is a consequence of ES 
and NB cancer transformation, we will analyze the expression profile of KCNA5 
in the ES and NB cells of origin before and after exposure to their oncogenic 
drivers. In ES, the two proposed stem cells of origin are mesenchymal (MSC) 
and neural crest stem cells (NCSC) and the driver is an EWS-ETS oncogenic 
fusion gene, which often is the EWS-FLI1 fusion. In NB, the stem cell of origin is 
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the neural crest stem cells and the oncogenic driver is usually MYC-N. Assuming 
that the MSC and NCSC cells express KCNA5, this experiment would determine 
if the repression of KCNA5 is a result of the oncogenic drivers for both ES and 
NB. 
Together, these preliminary studies would allow us to discern whether 
repression of KCNA5 is an inherent feature of ES and NB cancer transformation 
or factor associated with tumor relapse.  
Therapeutic implications of Epigenetic Modifiers 
Epigenetic abnormalities play a large role in cancer development and 
progression (136, 179, 215, 294). This thesis and current research demonstrate 
that cancer cells are reliant on specific epigenetic pathways and are therefore 
considered to be epigenetically vulnerable (180, 295, 296). Due to the dynamic 
nature of epigenetic modifications and the reliance of cancer cells on epigenetic 
pathways, epigenetic modifiers have become appealing pharmacologic agents.  
The current epigenetic agents approved by the FDA for anti-cancer 
therapy include DNMT inhibitors (5-azacytidine and Decitabine) for 
myelodysplastic syndrome (MDS) and leukemia and HDAC inhibitors (vorinostat, 
romidepsin and belinostat) for cutaneous and peripheral T-cell lymphoma (173, 
215).  Currently, no FDA approved epigenetic therapies exist for pediatric 
cancers. However, multiple clinical trials, both completed and ongoing, are 
assessing tolerance, combination therapies and optimal dosing of DNMT and 
HDAC inhibitors in pediatric patients (www.cancer.gov/clinicaltrials). Of the 
completed trials, Phase I trials with the HDAC inhibitors vorinostat and 
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bortezomib in children with refractory solid tumors and recurrent solid tumors 
showed promise as the drugs were well tolerated and had minimal toxicities 
(297). The data gathered from these clinical trials provide a starting point towards 
the incorporation of epigenetic modifiers in pediatric treatment regimens, for both 
initial and relapsed treatments.  
The clinical success of DNMT and HDAC inhibitors propelled scientific 
investigations and led to the discovery of numerous other epigenetic regulators 
that can be therapeutically targeted (e.g. EZH2 (298) and LDS1 (299)). In the 
pediatric cancers ES and NB, targets that show promise include the aberrantly 
upregulated PcG proteins, BMI-1 (228, 300, 301) and EZH2 (178, 228, 302, 303), 
the histone demethylase LSD1 (304, 305) and DNA methylation (173, 306-308). 
Inhibition of these proteins results in anti-cancer effects ranging from decreases 
in tumor growth and cell proliferation to cancer cell death. Work from Chapters 
Two and Three of this thesis specifically demonstrate the therapeutic potential of 
inhibiting the PcG proteins, BMI-1 and EZH2, and DNA methylation in both ES 
and NB. In Chapter Two, the data clearly demonstrate that inhibiting BMI-1 or 
EZH2 sensitizes ES and NB cancer cells to physiological stress, consisting of 
hypoxia and growth factor deprivation. This data are significant because they 
suggest that targeting and inhibiting BMI-1 and/or EZH2 could sensitize cancer 
cells to their existing hypoxic microenvironment, prominent within rapidly 
expanding tumors, and its death signals. Chapter Three of this thesis, and work 
by others (221, 307), provide convincing data that low-dose exposure to DNMT 
inhibitors could have therapeutic gain in ES and NB. The data demonstrate that 
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exposure to low-dose DNMT inhibitors causes re-expression of tumor 
suppressors (e.g. KCNA5 (Chapter 3), CLU (309, 310), RASSF1A (311)) and 
leads to a significant reduction in cell proliferation. Together, this work 
contributes to the strong rationale for the utilization of epigenetic modifiers as 
therapeutic agents in ES and NB.  
A novel finding in this thesis is that the PcG proteins, BMI-1 and EZH2, 
and DNMT enzymes all target and repress the potassium channel gene KCNA5. 
Furthermore, inhibition of these epigenetic regulators led to the re-expression of 
KCNA5 and its channel, Kv1.5, which sensitized cancer cells to physiological 
stress or had an anti-proliferative effect. Therefore, epigenetic modifiers could be 
used in the context of promoting Kv1.5 expression in ES and NB, which could 
then open up the possibility of pairing epigenetic modifiers with drugs that utilize 
a Kv1.5-dependent mechanism, such as DCA. Preliminary evidence in Figure 
4.2B suggests that the combination of an epigenetic modifier with DCA has 
therapeutic benefit as the BMI-1 knockdown ES cells treated with DCA had a 
significant anti-proliferative effect. Pairing epigenetic modifiers with drugs that 
utilize tumor suppressor re-expression could provide novel combination therapies 
useful in combating primary and recurrent ES and NB.  
A major challenge moving forward will be determining where and when to 
incorporate epigenetic-targeted therapies in current pediatric treatment regimens, 
as we are currently unaware of how to appropriately utilize these drugs. Ongoing 
clinical trials (www.cancer.gov/clinicaltrials) and research (173, 295, 312-314) are 
working towards determining how to incorporate epigenetic modifiers in therapy. 
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Data from Chapters Two through Four of this thesis, suggest utilizing epigenetic 
modifiers either as a pre-treatment strategy or in combination with chemotherapy 
agents. The rationale for use of epigenetic modifiers as a pre-treatment strategy 
stems from the data demonstrating that inhibition of EZH2, BMI-1 or DNA 
methylation alone sensitized cancer cells to their existing microenvironment. 
Therefore, utilizing epigenetic modifiers as pre-treatment could re-express 
numerous tumor suppressors pathways and increase the efficacy of existing 
treatments. A second option could be utilizing epigenetic modifiers in 
combination with chemotherapeutic agents. In solid tumors, many resistant 
cancer cells reside in the core of the tumor and are therefore important targets to 
eliminate (315). Due to their location within a tumor, these cancer cells are 
exposed to hypoxic conditions and growth-factor deprivation. In Chapter Two, I 
demonstrated through inhibition of BMI-1 or EZH2, I was able to sensitize cancer 
cells to these two stressors. Logistically these cancer cells are difficult to target 
as they have many layers of cancer cells surrounding them. Therefore, in order 
to target these cells we would have a treatment regimen that started with a 
combination of chemotherapeutic agents, then treated with an epigenetic 
modifier and then finished with a second combination of chemotherapeutic 
agents. The rationale for starting with chemotherapeutic agents would be to rid of 
the outer layer of cancer cells, so to increase the probability the cancer cells at 
the core of the tumor are targeted by the epigenetic modifiers and second round 
of chemotherapeutic agents. Future in vitro and in vivo studies will specifically 
determine if the second option of treatment is viable in ES and NB. These studies 
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will determine if this treatment regimen effectively targets and eliminates these 
cancer cells and whether this combination is tolerated in vivo.  
Though my initial studies support the utilization of epigenetic modifiers in 
treatment strategies, continued work needs to determine whether epigenetic 
modifiers should be used prior to, in combination with or after chemotherapy 
and/or radiation. Furthermore, we need to determine if we can use epigenetic 
modifiers as a therapeutic option in relapsed disease. To address this, studies 
will need to conduct in vitro and in vivo studies exposing resistant cancer cells 
and relapsed tumors to epigenetic modifiers and determine if they can be re-
sensitized to chemotherapeutic agents. Though current work demonstrates the 
therapeutic benefit of utilizing epigenetic modifiers in pediatric cancer, further 
research, an example of which is discussed above, is required before we can 
successfully incorporate epigenetic modifiers into standard practice for primary or 
recurrent disease. 
Summary 
In summary, the work in this thesis demonstrates a novel mechanism by 
which epigenetic suppression of the unique Kv channel, Kv1.5 promotes 
tumorigenesis. We show that the PcG proteins, BMI-1 and EZH2, and DNA 
methylation suppress the KCNA5 locus in the pediatric cancers, ES and NB. 
Specifically, we demonstrate that physiological stress upregulates PcG-
dependent suppression of KCNA5 and inhibition of either BMI-1 or EZH2 
promotes Kv1.5-mediated apoptotic cell death in response to hypoxia. In 
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addition, we elucidated that under ambient conditions hypermethylation of the 
KCNA5 promoter promotes cell proliferation and that inhibition of DNMTs 
restores KCNA5 expression and results in decreased cell proliferation. 
Significantly, both functions of Kv1.5 in mediating cancer cell proliferation and 
survival were found to be, at least in part, dependent on inhibition of potassium 
efflux. Together, these studies identify the Kv1.5 channel as a novel tumor 
suppressor that is epigenetically silenced in cancer cells to promote 
tumorigenesis. This thesis has provided a starting point for further studies 
elucidating the impact of the Kv1.5 channel on cancer biology and contributed to 
the growing literature demonstrating the importance of understanding ion channel 
regulation in cancer.   
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Figure 4.1. Model 
To survive physiological stressors (i.e. oxidative, chemical and metabolic stress) 
and promote cell proliferation, cancer cells epigenetically suppress the KCNA5 
locus. The PcG proteins, BMI-1 and EZH2, and their respective histone 
modifications (H2AK119Ub1 and H3K27me3), along with DNA hypermethylation, 
silence the locus and prevent transcription. Silencing the KCNA5 locus 
downregulates the redox sensitive Kv1.5 channel, which specifically prevents 
apoptotic-mediated cell death in cancer cells and promotes cell proliferation. 
Downregulation of Kv1.5 prevents potassium efflux out of the channel, which in 
turn increases the intracellular potassium concentration and prevents caspase 
activation. As the Kv1.5 channel is suspected to regulate the G1/S transition in 
the cell cycle, downregulation of Kv1.5 would promote cell proliferation. In 
comparison to cancer cells, non-transformed cells express KCNA5 transcript and 
Kv1.5 channels, as they do not dysregulate the epigenetic machinery to silence 
the KCNA5 locus. Therefore, when non-transformed cells are exposed to 
physiological stressors they undergo apoptotic-mediated cell death.  
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Figure 4.2. DCA Treatment in LoVo and BMI-1 Knockdown ES Cells. 
(A) A cell assay in LoVo cells treated with vehicle control (DMSO) or DCA at 20 
or 40 mM from either Sigma or Tocris. After 48 hours, DCA at both 20 and 40 
mM significantly reduces cancer cell proliferation compared to vehicle control. (B) 
A 48-hour cell proliferation assay was conducted in the control ES cell line, TC-
71 shNS, and the BMI-1 knockdown cell line, TC-71 shBMI-1 156. The cells were 
treated with vehicle control (DMSO), 10 mM DCA, 10 mM DCA and DMSO or 10 
mM DCA and 310 µM DPO-1 (Kv1.5 channel blocker). The control cells (TC-71 
shNS) are not affected by DCA or DPO-1, as the total numbers of live cells are 
similar across all conditions. While, the BMI-1 knockdown cells treated with 10 
mM DCA or 10 mM DCA and DMSO have a significant decrease in cell 
proliferation compared to vehicle control. Upon treatment with 310 µM DPO-1, a 
specific blocker of Kv1.5, the proliferative phenotype is partially restored in the 
BMI-1 knockdown cells. * p<0.05 (mean ± SEM, n=3) 
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